<div id="page0" style="width:595.3pt;height:793.7pt">
<p style="top:91.2pt;left:60.7pt;line-height:13.0pt"><span style="font-family:QlgxmbAdvTTaf7f9f4f.B,serif;font-size:13.0pt;color:#ffffff">REVIEW</span></p>
<p style="top:91.2pt;left:461.4pt;line-height:13.0pt"><span style="font-family:QlgxmbAdvTTaf7f9f4f.B,serif;font-size:13.0pt;color:#ffffff">Open Access</span></p>
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,669,157.66667)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAACsAAAAqCAYAAAAqAaJlAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAA1ElEQVR4nNXDiw5CAAAF0Pv/H1bpRRm9SEWIGaMYxu077tkOoGSe
Z6rENE1UiXEcqRLDMFAl+r6nSnRdR5Vo25Yq8f39qBJN01Al6rqmSlRVRZUoy5Iq
URQFVSLPc6pElmVUiTT9UCWSJKVKxHFClYiiN1UiDCOqxOsVUiWejydVIggeVIm7
H1AlfM+nSng3jypxvVypEufzhSrhuieqhOO4VAnbdqgSx4NNlThYR6qEZVpUCXNv
UiX2O5Mqsd3sqBKb9ZYqYRhrqsRyaVAlFosVVf4BJ9Uc9i1sdQQAAAAASUVORK5CYII=">
<p style="top:120.9pt;left:56.7pt;line-height:23.4pt"><span style="font-family:TqgscwAdvTTe45e47d2,serif;font-size:23.4pt;color:#131313">Safety and efficacy of cell therapies in</span></p>
<p style="top:146.9pt;left:56.7pt;line-height:23.4pt"><span style="font-family:TqgscwAdvTTe45e47d2,serif;font-size:23.4pt;color:#131313">pediatric heart disease: a systematic review</span></p>
<p style="top:172.9pt;left:56.7pt;line-height:23.4pt"><span style="font-family:TqgscwAdvTTe45e47d2,serif;font-size:23.4pt;color:#131313">and meta-analysis</span></p>
<p style="top:207.0pt;left:56.7pt;line-height:10.7pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:10.7pt;color:#131313">John Martinez</span><sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.6pt;color:#131313">1</span></sup><sup><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.6pt;color:#131313">&#x2020;</span></sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:10.7pt;color:#131313">, Sarah Zoretic</span><sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.6pt;color:#131313">1</span></sup><sup><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.6pt;color:#131313">&#x2020;</span></sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:10.7pt;color:#131313">, Axel Moreira</span><sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.6pt;color:#131313">1,2</span></sup><sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:10.7pt;color:#131313"> </span></sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:10.7pt;color:#131313">and Alvaro Moreira</span><sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.6pt;color:#131313">1,3*</span></sup></p>
<p style="top:245.9pt;left:63.2pt;line-height:10.3pt"><span style="font-family:QlgxmbAdvTTaf7f9f4f.B,serif;font-size:10.3pt;color:#131313">Abstract</span></p>
<p style="top:264.1pt;left:63.2pt;line-height:10.0pt"><span style="font-family:HqrmbcAdvTT99c4c969,serif;font-size:10.0pt;color:#131313">Background:</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:10.0pt;color:#131313"> Adult clinical trials have reported safety and the therapeutic potential of stem cells for cardiac</span></p>
<p style="top:276.1pt;left:63.2pt;line-height:10.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:10.0pt;color:#131313">disease. These observations have now translated to the pediatric arena. We conducted a meta-analysis to assess</span></p>
<p style="top:288.1pt;left:63.2pt;line-height:10.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:10.0pt;color:#131313">safety and efficacy of cell-based therapies in animal and human studies of pediatric heart disease.</span></p>
<p style="top:303.1pt;left:63.2pt;line-height:10.0pt"><span style="font-family:HqrmbcAdvTT99c4c969,serif;font-size:10.0pt;color:#131313">Methods and results:</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:10.0pt;color:#131313"> A literature search was conducted to examine the effects of cell-based therapies on: (i)</span></p>
<p style="top:315.1pt;left:63.2pt;line-height:10.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:10.0pt;color:#131313">safety and (ii) cardiac function. In total, 18 pre-clinical and 13 human studies were included. Pre-clinical: right</span></p>
<p style="top:327.1pt;left:63.2pt;line-height:10.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:10.0pt;color:#131313">ventricular dysfunction was the most common animal model (80%). Cardiac-derived (28%) and umbilical cord blood</span></p>
<p style="top:339.1pt;left:63.2pt;line-height:10.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:10.0pt;color:#131313">(24%) cells were delivered intravenously (36%) or intramyocardially (35%). Mortality was similar between cell-based</span></p>
<p style="top:351.1pt;left:63.2pt;line-height:10.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:10.0pt;color:#131313">and control groups (OR 0.94; 95% CI 0.05, 17.41). Cell-based treatments preserved ejection fraction by 6.9% (</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:10.0pt;color:#131313">p</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:10.0pt;color:#131313"> &lt;</span></p>
<p style="top:363.1pt;left:63.2pt;line-height:10.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:10.0pt;color:#131313">0.01), while intramyocardial at a dose of 1</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:10.0pt;color:#131313">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:10.0pt;color:#131313">10 M cells/kg optimized ejection fraction. Clinical: single ventricle</span></p>
<p style="top:375.1pt;left:63.2pt;line-height:10.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:10.0pt;color:#131313">physiology was the most common cardiac disease (</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:10.0pt;color:#131313">n</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:10.0pt;color:#131313"> = 9). Cardiac tissue was a frequent cell source, dosed from</span></p>
<p style="top:387.1pt;left:63.2pt;line-height:10.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:10.0pt;color:#131313">3.0 &#xd7; 10</span><sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">5</span></sup><sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:10.0pt;color:#131313"> </span></sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:10.0pt;color:#131313">to 2.4 &#xd7; 10</span><sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.1pt;color:#131313">7</span></sup><sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:10.0pt;color:#131313"> </span></sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:10.0pt;color:#131313">cells/kg. A decrease in adverse events occurred in the cell-based cohort (OR 0.17,</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:10.0pt;color:#131313"> p</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:10.0pt;color:#131313"> &lt; 0.01).</span></p>
<p style="top:399.1pt;left:63.2pt;line-height:10.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:10.0pt;color:#131313">Administration of cell-based therapies improved ejection fraction (MD 4.84; 95% CI 1.62, 8.07;</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:10.0pt;color:#131313"> p</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:10.0pt;color:#131313"> &lt; 0.01).</span></p>
<p style="top:414.1pt;left:63.2pt;line-height:10.0pt"><span style="font-family:HqrmbcAdvTT99c4c969,serif;font-size:10.0pt;color:#131313">Conclusions:</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:10.0pt;color:#131313"> In this meta-analysis, cell-based therapies were safe and improved specific measures of cardiac</span></p>
<p style="top:426.1pt;left:63.2pt;line-height:10.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:10.0pt;color:#131313">function. Implications from this review may provide methodologic recommendations (source, dose, route, timing)</span></p>
<p style="top:438.1pt;left:63.2pt;line-height:10.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:10.0pt;color:#131313">for future clinical trials. Of note, many of the results described in this study pattern those seen in adult stem cell</span></p>
<p style="top:450.1pt;left:63.2pt;line-height:10.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:10.0pt;color:#131313">reviews and meta-analyses.</span></p>
<p style="top:467.1pt;left:63.2pt;line-height:10.0pt"><span style="font-family:HqrmbcAdvTT99c4c969,serif;font-size:10.0pt;color:#131313">Keywords:</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:10.0pt;color:#131313"> Regenerative medicine, Stem cells, Cardiology, Pediatric, Heart</span></p>
<p style="top:497.3pt;left:56.7pt;line-height:10.3pt"><span style="font-family:QlgxmbAdvTTaf7f9f4f.B,serif;font-size:10.3pt;color:#131313">Background</span></p>
<p style="top:509.7pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Less than one half of patients diagnosed with critical</span></p>
<p style="top:521.7pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">congenital heart disease (CCHD) will survive into adult-</span></p>
<p style="top:533.7pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">hood [</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">1</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">]. CCHD represents a group of cardiac condi-</span></p>
<p style="top:545.7pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">tions requiring surgical intervention within the first year</span></p>
<p style="top:557.7pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">of life and affects ~ 1 in every 500 births in the USA</span></p>
<p style="top:497.7pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">annually [</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">2</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">,</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff"> 3</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">]. Although surgical advancements have</span></p>
<p style="top:509.7pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">prolonged survival, many patients will develop cardiac</span></p>
<p style="top:521.7pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">morbidities that will eventually necessitate heart trans-</span></p>
<p style="top:533.7pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">plantation. As pediatric donors are scarce, novel therap-</span></p>
<p style="top:545.7pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">ies are warranted to preserve cardiac function, reduce</span></p>
<p style="top:557.7pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">morbidity, and improve overall outcomes.</span></p>
<p style="top:569.7pt;left:312.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Literature in adults suggests regenerative therapies are</span></p>
<p style="top:581.7pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">safe and efficacious in patients with myocardial infarc-</span></p>
<p style="top:593.7pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">tion, heart failure, and dilated cardiomyopathy [</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">4</span><span style="font-family:DljwryAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">7</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">].</span></p>
<p style="top:605.7pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">These findings have prompted further investigation into</span></p>
<p style="top:617.7pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">the use of cell-based/derived therapies (CBT) in CCHD.</span></p>
<p style="top:629.7pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Animal models mimicking CCHD have consistently</span></p>
<p style="top:641.7pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">demonstrated that stem/stromal cell therapies are safe</span></p>
<img style="position:absolute;transform:matrix(.319947,0,-0,.31894506,14.7313389,805.9281)" src="data:image/jpeg;base64,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">
<img style="position:absolute;transform:matrix(.31997533,0,-0,.31813593,84.375339,844.48818)" src="data:image/png;base64,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">
<p style="top:661.9pt;left:180.3pt;line-height:6.8pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:6.8pt;color:#131313">&#xa9; The Author(s). 2020</span><span style="font-family:HqrmbcAdvTT99c4c969,serif;font-size:6.8pt;color:#131313"> Open Access</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:6.8pt;color:#131313"> This article is licensed under a Creative Commons Attribution 4.0 International License,</span></p>
<p style="top:669.9pt;left:180.3pt;line-height:6.8pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:6.8pt;color:#131313">which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give</span></p>
<p style="top:677.9pt;left:180.3pt;line-height:6.8pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:6.8pt;color:#131313">appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if</span></p>
<p style="top:685.9pt;left:180.3pt;line-height:6.8pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:6.8pt;color:#131313">changes were made. The images or other third party material in this article are included in the article&apos;s Creative Commons</span></p>
<p style="top:693.8pt;left:180.3pt;line-height:6.8pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:6.8pt;color:#131313">licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&apos;s Creative Commons</span></p>
<p style="top:701.9pt;left:180.3pt;line-height:6.8pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:6.8pt;color:#131313">licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain</span></p>
<p style="top:709.9pt;left:180.3pt;line-height:6.8pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:6.8pt;color:#131313">permission directly from the copyright holder. To view a copy of this licence, visit</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:6.8pt;color:#0000ff"> http://creativecommons.org/licenses/by/4.0/</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:6.8pt;color:#131313">.</span></p>
<p style="top:717.9pt;left:180.3pt;line-height:6.8pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:6.8pt;color:#131313">The Creative Commons Public Domain Dedication waiver (</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:6.8pt;color:#0000ff">http://creativecommons.org/publicdomain/zero/1.0/</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:6.8pt;color:#131313">) applies to the</span></p>
<p style="top:725.9pt;left:180.3pt;line-height:6.8pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:6.8pt;color:#131313">data made available in this article, unless otherwise stated in a credit line to the data.</span></p>
<p style="top:581.6pt;left:56.7pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt">* Correspondence:</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#0000ff"> MoreiraA@uthscsa.edu</span></p>
<p style="top:589.0pt;left:56.7pt;line-height:5.3pt"><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:5.3pt">&#x2020;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt">John Martinez and Sarah Zoretic contributed equally as co-first authors.</span></p>
<p style="top:598.0pt;left:56.7pt;line-height:5.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:5.3pt">1</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt">Department of Pediatrics, University of Texas Health San Antonio, San</span></p>
<p style="top:608.6pt;left:56.7pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt">Antonio, TX 77229, USA</span></p>
<p style="top:616.0pt;left:56.7pt;line-height:5.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:5.3pt">3</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt">Department of Pediatrics, UT Health San Antonio, 7703 Floyd Curl Drive, MC</span></p>
<p style="top:626.6pt;left:56.7pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt">7812, San Antonio, TX 78229, USA</span></p>
<p style="top:635.5pt;left:56.7pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt">Full list of author information is available at the end of the article</span></p>
<img style="position:absolute;transform:matrix(.3199981,0,-0,.32,264.07008,1.9093399)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAArAAAAB+CAIAAABTW7UMAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAt10lEQVR4nO2diXsVRbrG7/8zLidAEAJJSICEkBCWsAzIvhhAkG3Y
BtkUQVQEHRgxSASMbJFhURRxwAUEREGEmwkXDILKjSwKSAAHuLfvm9PX4jvVy6nT
p3NywPf31DOPQ/pUV1d/9dVb1VVf/YdFCCGEkD88/9HcBSCEEEJI80NBQAghhBAK
AkIIIYRQEBBCCCHEoiAghBBCiEVBQAghhBCLgoAQQgghFgUBIYQQQiwKAkIIIYRY
FASEEEIIsSgICCGEEGJREBBCCCHEoiAghBBCiEVBQAghhBCLgoAQQgghFgUBIYQQ
QiwKAkIIIYRYFASEEEIIsSgICCGEEGJREBBCCCHEoiAghBBCiEVBQAghhBCLgoAQ
QgghFgUBIYQQQiwKAkIIIYRYFASEEEIIsSgICCGEEGJREBBCCCHEoiAghBBCiEVB
QAghhBCLgoAQQgghFgUBIYQQQiwKAkIIIYRYFASEEEIIsSgICCGEEGJREJCUceXn
n19f/urKV5fZ6dyZM9oF53/4Qf0V6edLl5qlnORB4sBnn/79laW2RW16a11zF+eB
Ymv1Jrtu8b+ffLS7uYtDQoCCgKSIutOnunbuWJjfoTHl5cJTaxccPXwY/25fUNQp
/1Ttv5qlnORBYsXSl//fqPJyhw8c0NzFeaAYXz5K1e2iZ+Y1d3FICDSVIGi4fv3i
T/UX6uuvXb165/btJroLMeffv/32y+XLeCOXLl680dDwv//zPykuQO2JE5GH/6TS
R+/v1C7Yt3ePvOD40aMpLiF58Jg7c7qyqM4dcpq7OPe4e+fOlZ9/Rnv89drV5i5L
QHp1K1Z1O3Hs6OYuDgmBMAXB118efuWlF0YNGVhc0CmvfVa7xzKRcrPaoB32Kuk6
duTwJc8v/Hj3h+iWQrwp8QIe58uDB/+25MUnRw3vUVzUMad9dtvHslq3at+mdV52
FobgA/v2nj7pqbWrKtD13r17t6nLc7LmP1s8+rDyIP/c9YF2wf5PPlF/zXj4TyeO
fR3gLseOfLXshedhhz7pjddWVK+v2rNr16na2ps3boTxcCRNeXb2LGVUXTt3bO7i
WLDqFxcuGNSvD7xiTts2aI/wkCjY6BFDN6xdc/3Xa+Hebvs71XGbQ6JpU9X/f3np
27O7qtu/PDUu3JKTZiEcQYBuHr1Lhhje+SR0S+XDBm+t3nT1ypVQ7k40Ll28iHZb
UtDJ5HU09r6PPFRS2PmFBc+gg2y6mYPUCIK/v7LU8KmRWkYegU6CL978dlXovpik
A+kjCP77xx+eGv0ETM7HIKEStmzcEOJN+5f1NG8OhklVIwXBg0eyguDO7dtPT/tL
MMPasnF9KM9AFOjO0SPmtmsb7I0Udcq/dfNmE5UtNYIAo/9gzw5f/FblG2E8KEkj
0kQQnD55siAv19AUVyx9Oaz7Dh3QL3RB0Kukq505BcGDR1KCAGqgfNgQV6OBEG7T
qgWSlyJum9nyQn29M88bDQ2Lnpk3b9bMbdWbkynbH5Dv6r4d0KfMqxmji81sEcEb
ad0ikvHIQ67XLF38fNMVL80FgZ0mjC2/e+dOGI9L0oJ0EAQN1687p+tKCjuPGTFs
0rgxA/v2RqvU/rp394eh3LppZgjy7cwpCB48khIEsrHZCcOs5+bOhq8/Vfuviz/V
I0EaH/js081vV6GP7929BL2RfeWTo4a75vnJR7vtC8Y9MSKZsv3ROPLFofzsdq6t
d86MadvfqT525Kvvz3536cKFH78/d/zo0V3v7Vi6eNHQx/tntW5lX5nbru21q024
vin1gqBV5JHZ06cumj/vXnpm3oK5s6dPnjhq6CB45MzfrVEm+OgwHpekBekgCF55
6YXYJtkR/b38Nne2rm7CmHJ5Tc/iolCW9WyqWgeDj2kCWnpmHpy2ui+cgN/F8+fB
va+pWGlnTkHw4BFcENQc/0b6d6T5s2bG/RB75tvTq19bUVZa8sGO7a4XqFXBtDBz
TtbUZLd9TOvYykqLd27b+u/ffvP/7YX6+qo3K3t1K4bbauJCploQtM1seaOhwefi
utOnVix7uWNOe63qwv2OS5qRZhcEd+/cwX1VGWBs9efPu15ZPmywtH8o+NSUcOTg
gcJplJj/kILgwSO4IJg7c5qmBpIvDURx8e9za7QwQyDCnBOSi5+dn+huz6beiJh6
QdCmVYv//vGHuD+5dPHioH59ZO2VFHbmh4MHg2YXBBCd8rNp5euveV2JIZa8cu2q
itSUcOjj/dVN1foAEygIHjwCCgJ0HqVFhcoa8rKzQlmMduLYsRa/f96mhRkyc8ok
2ZmhK123elVzF8qFtBUEVjSKYn7sPMEXn38e4O4k3Wh2QaBZdc3x415XQoPKySpo
+tSUkIKAKAIKAjhQOUc9YWx5KKVZ+eoylefUCeNDyfPB5qtDh7QVgiuWhbZEOVzS
WRBYjv2Kf1vyYoC7k3Sj2QXBnl27pFWfqq31uhKjLPk5/7m5s1NTQgoCoggoCC7+
VN/usUxlDYvmhxC38psjR0oKO0uRcaOh4fqv17Tk/1UY/HL58qH9+za/XWVHzt+w
ds3+j/e67mhw8u/ffvv12lWvu9Sd+q/3t2+rXPkasl27qmL3zvfOfHs6bp6nav+l
frWmYuUHO7afrKkJa35+2MD+shsbOXhgKNl6gWLjcfAIla83Pg7+F49m+DhpLghq
T5xoIaSV4dJCWMuXBw++s+HtiqixVb1Z+emef5rfVHK2rg6/3VS1zs4KprJ188Yv
Pv/8x+/PJZoVrPfrLw9v2bihYsVyZPVW5Rt7d3/4/dnvApTKBr898NmnjY8ZzRDv
ffs71biFSfCGO7dvq8brtBP89cgXh9BIkS0yxy3QeP2/dl26cAHXbNm4Hu9aFQbK
2PXwC39BAD8G52DfvdFXrFv7yUe7nadsJAPcmgzQglfsdSUKI7cbwH2FWAwfmkgQ
wJ4/+mAn/KR6swf3fYZ3F7icsOqjhw+jUdhGWFW52tyq/Y0Qbj8hI6w/fz5qgRtW
Ry0Q/4v/Pnzgc5OYe3fv3FElca4bxUjbXoOvDBJe0afSZM8YLMaarJlrV68GFAQo
Yvs2rZU1zJ05LVg+VrSC0LOOGPS4tkExs0UkLzurQ7u2WoLJei2UQ9t+ctRw5/I6
JMgX3MJrJaNi8bPzc6N36ZSbrUwNBgRb6dOjtFXGo1q2mRmP9unRDQ7XaWToKvBG
exYXOTde4l+6dSnAGDTJqKU1x4/LPuyxlhkmAiUY8FZLFz9fWlTo9ThLFy/yb+1p
LgjQFKVJx417Dw8C0dDBLeRD28yWg/r12Vq9yeS+P5w7h6qDnbR22/JgP0WP4qLZ
06fC/cVdIlpz/JvpkyfmO5ZJ2ubRv6wnLNlQjMJToHfEfbsXFeK3rmXLa5+FSoCb
9skHIin398a7b+8emT88abFj+QvegutuFzw7HOWQ/v3kUET7IR4QVipPwfASBBi4
jxo6yDUrPGzv7iUoW9yxhwlo49Ij+ay1Wr/2TVkM52EfTUS4ggCvCV01/uRqz6hw
jGHe27oloRLCFczwtepNb63zt2p/I5SrPlU5nUYIdf7c3NllpSVqZ5aW8KJHDx/q
f84T/J7qy6A81L9D0U4YU57Tto1rpcFWnQ4TPDtnVm5WGzu3jjntEz3/BZWGt69q
Bn1ZQEGAty4/d6GVBssHBUI/7Vq5XglV5nSLGBxo+3a80qghA8//4NlJwOzUlXAZ
VnRNkMle3gF9yuRIDi+vS8e8uL/q2jkfw6xgVQdgnTK3aROb6iMLXJVJsKP87HY+
vWCaC4JbN29Kk0aP7nVlw/Xr6HS1LTauafCf+8J+fG4KZ+TVvbmmzh1yThw75poV
GsW8WTOdmtWZIG29MrGBNvr7K0udXbVXgiL0mSOU3wEx4rH/EcpVdicy9ejaxZkJ
xpqlXQoMy/PU6CfUD6UgKOrUuIEe0hZe2yQf1AAGgj4VZQhGKSpPqBYUwHkNuh/5
vQBdVFzxFxYhCgL0ahCvJnULt++120KCSoCEauUb3vF3q+7mY9XSCNWhl35GWFyk
fgvPAAcIHWDeTlEbXq9v+5Zqddm8qDq8e/cuntHEn4wdOVybBpM+M5L4VP3xo0fl
z2dOmRR8l8Hg/n1VRvC8ASY2rWhduGoin4Thl1bXp2przZ1XJOpVT9bUuJZn1tQp
6rK1qyogHfKyswyzhcOyR/zweiZv104QlXWn/itA1TWu6xQuMuORhzBmDZBPXGC1
Cb2g5S+/5JpPmgsCeGRpiuXDhrheBpOA0zSvDYyhvQbQ85/+a0IVi5ST1Qa9tTOr
Xy5f9olJ5UwY4vjMXcOQEi0YEgYrrrlVLH9VXWPH4MM4xrnVU9T8YC2HV156wTAs
up3kRKAUBFBCcFMJ+QqYUPLLS7VTu5whWG40NGghBeXYsakJRRAsfnY+KsprJsk1
detS4D/HDneqbf8JbNUxRrjMxAiHqN9CuPgHnHZNeMuukxbvbd2iroEwxTUY/Ztn
C58vfRp+Lo+YQteWkI5Em1W/RQ/yzZEjwQWBtggLI+8AmeB5qt6sVMdmyDcE03Q9
WqPy9dfkp5cL9fWFsTFBYRYTxpSvqViJUQV6HfTrGDFoscAK8zu42qIUBOOeGDmg
dy/1f8tKi1F961av2v5O9VuVb8ydOd05B4Ah+5cHD8pur6Sw8+zpU1HmbdWbIRSg
4Ho6FDQaZICq07YzYUjRFAcULZw3RystlPJLCxfgcT75aPfWzRvxRHLlh502rF3j
zCrNBQEchCzePLepXYgGubkmEp2xHD1iKN7v7p3v7d39YVXlagwO5KeHSFQT/HBO
l8vV66vkNS0eeWhg395LFy/asnE98kHlbKpah/8Ll9EpN1tdtuT5hc5S3bp5S5vE
wohq5OCBry9/dde7O5AbXsf0yRNzs2KUN5pJ7YkTrlWBVinHQ1AhyA1N791/bDl8
4HPIBTg1GIYc0dqvzHU8LX0xfoXSdu2cr/4ls0UEhZ8xeeKCubMnjRuDcZ4WuBf6
0ukW0ZfgYtghSoXRFYabBXm5tmjAY8qPqVIQ4EayolCxeFmVKxvXwcCY7XOAZJO3
E3JuuH49rv34o82DypW/p0+exFPLv6Y4JlsoggA+Fnau/i+aCd4LfPtH7+/8ePeH
sHY4T+fuaJ8zEtGxoUXIi+HuUI0Vv1s1Ru0wG23m0suqEzbC2KXZ48tHyVsM/nPf
FxY8A+8Hg4fc3/XeDjRMzTNEPFSdFAToC+ScNPwG2juMED0FHOzq11ZMnTDeGW4O
CkBaODo4+Vc4IsPXhxqWTbistNhKJg4BXC0G67IoeBjX2TBzZHOdOWVS3OsbP4HE
KusxI4a5rglC9zmkf8yVeMfOy6QgUAmm87FbJFFY1YsLF8gr0T0oA4W4gaNxFYl4
hXISDI4MMsKgemKQhhVpmk0Z2i3waK4f/+7euYP2JtUJemLnVHmaCwL05fJhXWMT
QSPKa4YN7O/60e78Dz/ADuWVsFJ5AZpiUad7/ghdzsF9n3kVDGaGv0JWohd0Cgug
HSYCNw2l77zs0oULcHaaZ/FaOQXJi5eFJoN68BrGXf/1mnSUjR5gxFDnZdIXw0pl
adHGndNjsslgwKfNDaD3OvDZp67rwo4d+QrtEQMV+e9SEKj9ODAMeFuvRVhwqdq0
JYzK9UpzztbVyW9DGb+f5IJ61r4ZDehTluITOEMRBOo1wVtiJOZ6PRwF3o5c9oT/
9prnnzMjJs4N7uUaqenSxYtQdTFWXdLVadXSCKdNTMwILdsOH3kIZcD78nIpuClG
R7Ik6O+dhiqdaob4D2gR128oV69cgfjQWoFcifLzpUvShFzboCsqKLA08qRCF0NG
RWILmp/THr1dYINOdB8LlJR5pwiXocl/57IdpyAoLujkr3KkxFNJrkl0BcOgmBf8
9F/jPqzG0sXPyxxCD2MCdy9X8WDg5bOF2nK8i7Ej9XnRdBYEaLfdhcDHIACORrsG
/YR8wPJhQ/yDF2kzgTu3bVV/On70qGrhEFKGctD1dtAK0llgUOXf+jTvCRnketmv
166aRMpDkWS9YYjjPMJU+mJUrG0DGJPFPaxEG8ZFomO7uEXScIZXxzDGR37ZwBSl
wMWQMdH7OsG4Vr4p1EDv7vpn6XFPjEj9edyhCALVBcZdaY/BdNx3evjA57KuBvXr
4x/nRrNqpzMMbIQ26Du+OmT0QVZOBUHuOL9Na6Ms29epE6W9WL/2Tbm9HOPJ0ydP
qr+i41N/wqDUZ5GcRA4P4CrtjXhJCQK4UW3MZKfCvNxlLzwPUZxohgkJArwk+bGg
R9cucaPLoRLl2lfnd2JNEJg4a3Q52veIDIOzSbRVmXhw/+udSCNA8l/aGgD5SQhP
9NH77qpfIk+6QtVpujudBYH2Od/5vSA6i16sLjCZRkYDk8odYlT9SS4s6twhJ9Fn
lMh5L4i2uNu6UGy5LCb5mIza2nhne5G+WL3c7e9UJ5qz1+kn/jgFgZcG0pBzPHCy
Jivg4qJNpMnUKuNRr8U3TU1YggCu1WttlgQ6T440+vQo9S9STlabuBPPNxoa5NR6
SUEnzaoDG2GiwIlJKeOcaHQKAsMQDvNj13LNnj5V/UnTTytfXRY3N23zC6zd/vdk
jz9GvU+bOF57QtWKMEjaunmj+UnzCQmC97dvk7fzmqfSwMhVdhiaqWmCYHD/viZ5
at+6DHt32aPDmtFOTH6lGDXkXgTyDO+Zt2DcuX1brpCIuwfPRhutag6uWQSB6950
yfdnv9Mm0tFDOxfuHfjsU3mN4ZqvWVMnq59IhYRGof4d3XPgLrnxPBExbjBxBED7
zmU49PFCW8vi3Gbi9MVPT/uLSc7yy3rgZcuaIOjaOd9wqQ0eRP4w7qSCCa5RxjOi
u1GaaEWwCWEJAvPYRNPFrKq25sNy7KY2tOqXhFU7P8I6jVB2qCECwZ0jFus4D4jR
BEFmi4jhXvHGVc8i57z2WaretKWFGBvH3VoMpSKLoVYeJCsIbDasXeOzGh+93bNz
Zvnvv7JJSBA8NfqJAO1cW8wFVSH/qgkCw3l42Jb8VYVZRJGKFcvVTxrnqBMM2SHX
37ZyDMeT5ND+ffKJdr27w+RX//7tN6n94ebkX1MvCCBJ4RfOnTlztq5OJfzfU7W1
6ODfqnwDg05tSzGa3PGjR53Zyo+OMHXDeV2IVJk5hrz2v6N3kU8aeEn5kkXPqXza
ZrZ0fuZw5ejhwz66LVHQycnlis7JT80Xt2/T2qScp0+elDoj8BIZTRCYxwNuNFfR
LW3fkuxoclv1Zm0ZpjKA5o01HpYg8Nm3orGmYqVspNrKGPkxtNGqzRwjFJW0ai3S
qNMI4w4VAiN3IcH8tL9qggCDSfOctUkC+clbLi1EPRw+EGdrjPy00Sk3W+1NCEcQ
WNHFHc/NnZ2T5bmHEC9+xuSJ/t8RzAWBtkLScMxh2Z9vRTuHrpR/lYLAfNgtLdh8
hSC6AfUr6MTv6r41fAQbWVetW0SCRcfzQj5Ru8cyXbe6uSI3o3bMaS/3wKReEGRE
I0ehcjJFwv/12tbcvagQY25nntoKA9flqK5AfMjAAGpQonWiGP4G62/kmhjzWCC/
XL4s90GMe2JkgFsrtC93m9+u0i7QfLHJYmHLsSTFcP7PiSYI4n7LU/z4/Tn5KTCZ
fYB43VPGP+nlGCPRj82Gowh0utvfqYa1QF6ENakQiiCAlzCJ02ezc9tW9UPtc7gV
O+FqOEdrOQKLaR+YghlhMPr16qFu5Pz4qAkCrQPyR5unlOtntcefPnmiTz6wbblB
dIEIkh2aILCB7IJH7t29RAuwrxIK7XPel7kg0DaJmYe+utHQINs5Gqr8qxQEKKqh
icvzzpG54ZoO+ckD/ZbJDIpENhs0qnBjFMoFcf3Lepr/UE4GastbUi8IzBO65yXP
L/RauFR//ry0mYTGc7LjhypX/66tCY1El2HG1fWShuvXZeZLFy8y/63c4xBg/YqG
/LoUVxAYbouSs24wJMPQ406kIEArM1/YpAkCe1NAACD0nbF6Jo0bo32oihicQgJ3
JIsU1ulHoQgC13BSXux6d8c93wXXJ2Y3G61a7CR03WfrhVyCqi1NCGaEwZB75ZyB
KTVBkNA6Bm1DgRZeXfre7LaPuYb7tJFOEj5ZjoJCFgSKb44cQVP0ivwwbeJ4148c
5oJAm4yF4rODP8dNcMSZ3usKpSAoyMs1/AwhBQGs2XDXcpKCIGY566MPo7tN6Of+
dBMhj0q7FBjWLZJUx5Apclde2gqCRfPn+c8ffnUoJlAP2qFhbfxtyYuyAUtpdef2
bemI1VMP6FO26a11JlMyp2pr5aQ6LNn8NUmfW1pUGPdekNEna2r2f7wX/qvqzUr7
lBAMbtAnoeeWvZS/IGjpGA56IQ/pMP8g6EQKgg7t2poHCw9FEJw7c0aLkoKaV8ss
tHXBSC8seMYnNzQZeXFC8tGHUASBFLtx+WDH9nteIlYQ4L+lVY8eMTSYVZcUdJJd
jDTCVok7W41bN29hAHZo/76d27ZuWLvGPlsBihzNAfYmZbq/IPAK3eGDDEanfW7Q
PpqogIxOoJbUZdp4oKkEgQ26RhTLNZglul7n9eaCAF4pUb/vmrTv3FIQyOiV/khB
kJ/T3v9oFkWSgmDi2NHyQUKMfH7zxg0ZYyRwanZBkPHIQ/AL3YsKZcJQRlvYFfcT
gJzhTCbJjQZ2PWvbpVRC1zVj8kT/dyoXIiSTunsLAnQ58HHQKCiPYbA2f0Fg/vlJ
RkZKaI5KQwqChOK4JS8I0G1oQS3xIFqUFOc+Z5+tlfLiRGPS+RCKIPAJMeTERxCE
ZdVdOubJtbrSCF03x5qAkTRc/ZD+/TDQzfQ4eURLcQRB41fpxLwcOiz1c+esjNzI
imbrmkPjKW7CD2vznU0rCGyg7iELnMfA2IcFSMwFgVyRl0zSRJZscj2DCgLDhpqk
INAOMgg8penkl8uXXQ+ISjS1bG5BAIfuulvMPtJDFlUGCXCiLUQNnFw7NtzaJxZy
nx7d0MW6bkPQ4ooEThhzODOH25LDCPPkLwhy2upLyl3BC5KiTQvrlBCBjz9OXhBo
G+7Rkbh6BmdocNez4iAv5ITrnBnBz5PTCEUQJLTq00cQaFO/gVNhfgcvQWBohJJ9
e/fACAMEMI4rCFyXMPsgJ4Y10QPQu6u/orSuu0DlJiNnwJVUCAIbSGMtaq82YLIS
EQTazDBqNljSFq3cR4JAi6znFUk+AJorzAhavRDRzS4IvL491xw/LpcWYrzlc7Sd
Fhw0sLF5rShG/wdjgF/2OpoIQwHnV0/NdQYulWbnDdeve50ThvpERaEw/Xr1gH8c
NXTQhLHluFg6yriCwOQIQbg5uS4h8NlpVvMJAm3lJtyCz4IkTdxH3A4qk+4iWGxT
L5ro+GMffASBFv4rsFUXx4YiCGCECnTqrkdptG4RgUSDnkY9wERHDRn41OgntMjl
TSoICvJytdlobWmhc7YJg3N5loc8BswmdYLAisbwkd9XGndmx/aCwWYI0M3AOZ6q
rQ2QtAWA95Eg+OLzz6V1OtVVYDRfNmncmGB1i3Yu7TXdAhNpIzOfg8I2Va2TV26t
3hSsQuLupK89cWLxs/O9zsmc//Rf5WdRbYbgrco3gpVKhtSE6co5STuhVS5/+aWD
+z5DZTpt+9bNm+ZrCEwFQazbuh9nCLRZpbjRkOQOUjtNGf+kXDkhV+eUlZYYnmFt
QloJAk3mrqlYGcyqMf70WkOQkCCYPukp7b10LypEI/10zz/RcFyXIUMxmwuCRL3c
8IED1M+LY9dJ2MjIuc7vSug1pLhxhuRPqSCwGhdXL5KVq+22MrcwGcUMT+gavD0A
95EguHb1quy2zSNWxgVWLtcQJNTUfUg3QQA1LVch4RV4HfYj/ReSPE+9Kbh189a7
/9iiRbtSmkBdpn1t3bp5Y/K31rolGHPcCJUXf6qXW5hCEQRW7BqCZPZBNJcgkOHa
slq3Mtn1rvnGSDR+nD3MlaEtI27Rn5IhrQSBZtWuR4oEIJgRwphlYfAeMTaIK8Xk
KUdxFxUmujJUfsjr1a3YecHXXx6WW/y0mUUZT6Uwv4NzuVuqBYGmUF6P3X1rbmHa
glvDkNRxuY8EgRWrFpEqVixPNAcvpE0ns6RLkm6CwHJ8dvGamtaOA/bZNxsue3bt
0sLdo1rUabxa6B705UneTtvUBLnpenSTxqULF5pCEPhPjZrTXIJA6jnzLXkrX12m
aYLRI4YeO/KVXIDVo7go3HNN00oQaIEvX0xkm74PAYwQJienqVDO/R/vjfsrbXIr
7rZDw5hvNlrAe6+dHVI0yCgjGOnJwHGu21ZTLQjw7uW3Wy2yo7mFabtTnAGhgnF/
CQKtP+vaOT+w39QYPXzovfaT1Sb541+ttBQEaL1lpcWyDl3H2RgEy4M9w5oyMQED
RC0Optp8rE3kjBo6KMl7acNQw8AGZ7493SrsNQRW7AedVonED9BoLkEg7SqhaHQY
I2lfrOXKkowmmKBKK0HQuMVJBL1NaDejDwGM8JsjR+SL0CLWeIHyy3nHuILAMDCz
DcYAsq25Lj61YrfgyYBR8nNMdMV3rfO3qRYEWq+gDWrNLQw9X2F+B3Wx+RZBf+4v
QaAN6RI1Lx+0wxjNg5L6kIaCwIoG/5LNHq/Pdau6DBXeuUNOWMLLEDncRK+mBojy
7G8M6M032bvywoJnAtT/nl27pKmEJQi0b/CBp46bSxDETO0m0staUYfuuorNpw9I
hrQSBFp5YNU+AXbMCWCEeOOy5g1j32nRQeIKAvOwp5bjuC+vSANXr1yR28RUkE25
ydlrU2KqBYH/hIm0MOcCSA25eiJAhAdX7i9BABbErk9+rGVGostWXUFnID9EBTto
TiM9BQHQFtU72zDQTjr336YYOmj50sDUUqbXY+OvoSNJ5i5acEDD8/20c+vDEgRn
6+rkyNjweC0nzSUI5NljCQX/tkE1ykkpOw3u3zfEtYSKdBMEq2N3kL1V+YZ5zl4E
MEKtcalPdf5Uvv6avzPResC89ln+JztL5Pk1zuNkJTOnTFJXlg8bbEWnLuSHJy8x
kWpBMHLwvXaS2SKiHWshz3LFw/tnpR3AE8oy+/tOEFy6cEGLGVCQl6sFPwkA/I78
eg3jSz4sWtoKArh+ecQRHtYpqhpPYBOF715UmOSpwQmx/Z1qdWt5QoQWk7xzhxzz
k0WdyDOgUQkmh2v8fOmSZn5hCQIrdl4ElR/sVMbmEgSagkxUq12or3eehNS/rGdT
HMmTboIAbVZadafc7OQ/WQYwQggRWfkms6TwCVrQs7iCIGI8+4X+Tp62Bf/sc7Fc
Wgg9Co/x8e4P1W99QjMFFATBgmRpU2HONVwyvjccTVzvpq3ETj64930nCKzY4aPq
GJI/rVX7otylY16SR8KnrSCwYt9gxGM+Ta6riDTx+Sgach6orLRYDhNlAPNI4xqi
EYHvosX2MImyPr58lGZ7IQoC7XzzHl27mI+lFM0lCPbt3SMLn5edZb4J6N1/bHGG
cbNTaVFh4GMdvEg3QWDFDnAjYcxQBjBCbQPksheej/sTTQUaCgK41riKB32KFvBX
HZ3qhfxotf/jvXNnTjd5WQEFAbre8mGDd27banj8D55nxbKXW8SeeORcHaMtso17
MCt0kBY9au7MaSZRqCA1qtdX7XpPX+F5PwoCy9ErRKJhgzHg0yZgfMBw0LmkXB5d
GIluez16+LBJbngveHfai0hnQXDr5i153k/E7Rjf0ydPyoGL3a5MPnCiG9tavUn2
KF8ePLh08SLDsh0/elSuFJE7D63owUvaGH3syOEXf4rfZ8BKd727Y8PaNepftMgW
ZaXFPksl8HPNa0fCFgTQPXLzfSQakCDuo+ECWbHNJQhQdfKETKRuXQrimjRewegR
Q521KhOyDfdo0zQUBLBqmIp8ashxc6t2zocHMEIYgIxPnJ/dzv8gZueu0YiZIGg0
7Mf7+3gSPFT5sCHyejiruL0Mmra6fuqE8XLjGDyt168CCgLlC+CMBv+5L/QBxEHN
8W/wIuH+7t65g4T+4Puz3+HeLy5cgKaoVYHrgcXaGeTo1aCDtM9myFb6qb+/slTL
GfeqWLEc/auc1EUmV37+Gb4VGU4YU463G3GLRXOfCoK7d+9q41c7ZbVuNe6JkWge
J44du3TxIgqGOkHtoSpwuwOffbpu9Sq8SngBFGD6pKe0bPH6tEMNcBlsC0pOM190
qMgQAuvZObNQbxnRW2utLp0FgeUINoAhmvO7r7aoJxKdjIH0waNJm4SxoX5Q56j5
KeOf7JSbHYldpWyf9oZuHgN69DRQY67fhlH415e/KtVAK7e1wSi5tgYtt13bJYue
QwGkKeIW0MG1J05s2bgB79o+dGfUkIHqAlxcHDvhOaR/v5rjx7Xb4dG2bt6ooo7i
RdutKRK2ILCikZpkr2z7ZTR5rcbss5dwazTtxvNUV97bF9qMoYudUXghKNHc0HzQ
t8Fg0BhR8nNnzmAABx+CIZ1zLeGkcWO2b6nWKgH9QaKnpfuQhoIAwJk4rfqlhQtg
1fA28spfr12NWvV6jItsq4Yz1HILZoTyhK1IdHrGOfOK/g6uTH3dRwuVx1n5CwK5
SqZLxzx04VogYTTJPbt2yZgcXs7TCaol5/cwgK1bRJTv1WI4agQUBNpWKOXE4R3y
srM65rRHQl+ijahUwiDGq0zlwwZrF/coLoL/wtAfNjewb2+4V81JOSdqItGuqyAv
F22sf1lP/C+aELSLZmHOszXvU0FgRTWBDDrhfDVwlPZ7QUJVOKPkzpo62Znt0cOH
ZXDJe40qq02Prl1Qt0gYssBNZ8ZmiHq4j2YIbLQDDlw169+WvOisjZaRR2CWfXp0
Q23AS3btnI/60YxNfmLQugo0V/RVIwcPhNiCneO+T41+ArnJlQ128pozq6pc7Txw
HNoa7xrexC4VHAFepTZLJ7cpW47vRLbPwjDdboDTJo4f3L+vtAfk9vHuDzEeUP8S
riCwouLJaauZjTWWj4Lh0WCHcDVypnDtqgr182YUBJZbTGI7QeTFdZKwChibnQ+0
u2YMhfkdwtIE6SkIrGjIcKdC0qy6xM2qJ4wt17IKZoRHvjikzUBnRMMB4WHRHKA/
Rgx6XDvR963KN+Q3XH9BUNqlQG7tiUS9NB4K4wRIW3SFciedSuYRR1x7BP9vHwEF
gTOgo2HC60cV+KyVPVtX5/X9TCWIRO1X6Aa82pVPcq45uH8FgQ0Gf861SIbJ63gS
jL3KSosTzQ0u774TBBhnyL4HpYVHcF4GIe/squMm6THlefCGKSPe2bjv/mOLq3Tz
T/YKZInsQf0Teiw7ZB6sTv1j6ILAikYhS+j4zdWvrXB9nNQLAiv6ddVrD6FPwojz
2JGvZD4Ym2qz6GjpXrE1EyJtBYEV1KrHjBim5RPYCLWlhf4tdMWyl63Y09L9BQFK
goGx67cGr+TvBDSOHz2qSSXU9plvT/v8JKAg2Ld3z4A+ZYZHQNoJrWt8+SiTGMM1
x7+R4aCdybWrQNt4ctTwTI/jYbSE7goq0jkdKk8oxxDEsDbk+VH2kk6TX2mjMcNz
4uNy7erVla8uKynsnFATQqtbU7HSK088EfI0lBroR3t3L0FD0mQfalte5lzA8eme
f8oLNIdoiPyEhCaaaDhn7YCDbl0KXJekQL1NGf+koQaFehg9Yqg8jQalGjtyuLmE
7dOj1Hk0qJMfzp2bOWWSc7uaV3scOXiga5QbdKgyKrZHkbqpJ4LUU//uXOskY1pA
QwRbMY4amzZxvEmNwclKrSkHSRDr5nf8/ux3hqfLx2Xv7g9l3+mT4FGHDuiH/tI1
H/h3rXfEu05+uzWG2irDhDSTXCSR0H56dPPyKVwj5CigzGZMnmhu1Ri1O0MKJmOE
cNRxXV9xQScV5PvqlSvKUJ3TrlIQ4HXbDgpvHK7G/xalXQqcPjMu8uVGDM4JS2rb
IbQGBgSzp0+FnkUPBGOF70N12wnvBmP9Xt2KJ40bg0GV+QI3K9oDwbMMHzgAbRj5
ZEZzy8vOQrtaOG+Oz/oLDGfx7vHDwvwOqjB4PfjvTrnZ+PmsqVNgjl7LQ7ZVb54+
eSK8Kkww7pJGBRr8jOivkDAgMAwsCt2jfjVnxrRwNxRBeGJIsWTRc2geJQWdsts+
hkpQtWHPWJaVlqBbgj79ePeHJvuk0YrQNqCZMIyA21UZ4tXkRr8gIDcocef8jc2F
+np4Z/t5kZxHc6KXVX9FQwp2NMP+Tz5RtQp5nmisHjTmuTOnqWKgE/IRat/VfVux
YvmooYOgHaXl479RvTA2lGTr5o1esxTnzpypqlyN1gH9BDvXcoAPguZ+bu7sRDeM
wIGuXVWBQRLeO160ek2NH/tz2uNeeIPV66v82yMqH/Y/sG9vNDq8X9tsoBLQB2As
uOvdHVLtobWiVdqtxjmnAu+s3ggeJ9gGJRtYCIQpTLpLxzxVXSheTlabnsVFqEm4
I61pv799m2rRhrEXbeBkYD92sfHbr780Wk7rA+oBcrNfrx62T7vXduAkS7pifLJu
9aq404RQ1fBgyj7xLvCaktwBi5HAjN+rCM7T/Id4F+qHKvqNCZrr0z6cuwKDRP3Y
Vg07dFo1qgJv38tpJGmE13+9hjZlfyBQzQGNC73ehDHlWzZu0JY1oBpxOxieM2CJ
toZAjddRJNgqhhlQBsq28R+QGrgF+qxgDUeb4Yi7xTG0OARwEOgw0KtBWSPB2aED
CDA9qHHr5s368+fP1tXhfxM6xPrO7duqMPB96PC0d/bHAa8G/SKaCl4KagMdBrq9
JGsDLcTOEOniT/WhxDa+f4FHhoHZxoYUwNhg579cvqxygOkm03Ha4L3jRcP4VZ4B
tu2h0UHQ4C0jn1BixoWCat0oGDzD/WV+eAtoMnbbCcVJ/qEIxaoDg3aNV2Y3BzTz
AHGipCBo0XjaoT58Qp7KFeA/kjy3Qobvg26Ou5M/1YGJCCGEkD8m2vHHoQSW9UKL
bW8SOoWCgBBCCEkFqRQEa1dV3LuX2VHLFASEEEJIKkilIOjTo5u6V/eiQpMPHBQE
hBBCSCpImSA4tH+fjE2iHSzsBQUBIYQQkgpSJgjkQT/ZbR8zPGSAgoAQQghJBakR
BNppbc6YvF5QEBBCCCGpoKkFwc0bNxY9ExPLv2NOe/NT0SkICCGEkFQQriA4tH/f
ovnz1q1etWXj+vVr35w3a6Z2/EHGw38yCXKqoCAghBBCUkG4gqCqcrV/wOOVry5L
KEMKAkIIISQVxAiCh/+UpCDYsHaNz7EO8thPQygICCGEkFSw/Z1q2W0HO8JN5uY8
zy+vfdb0yRNP1f4rQIYUBIQQQkgqOFlTs2j+vEXPNKbFz86/UF+fTG7Xf722d/eH
a1dVvLRwwcJ5c5Ysem7z21Una/4zcIYUBIQQQgihICCEEEIIBQEhhBBCLAoCQggh
hFgUBIQQQgixKAgIIYQQYlEQEEIIIcSiICCEEEKIRUFACCGEEIuCgBBCCCEWBQEh
hBBCLAoCQgghhFgUBIQQQgixKAgIIYQQYlEQEEIIIcSiICCEEEKIRUFACCGEEIuC
gBBCCCEWBQEhhBBCLAoCQgghhFgUBIQQQgixKAgIIYQQYlEQEEIIIcSiICCEEEKI
RUFACCGEEIuCgBBCCCEWBQEhhBBCLAoCQgghhFgUBIQQQgixKAgIIYQQYlEQEEII
IcSiICCEEEKIRUFACCGEEIuCgBBCCCEWBQEhhBBCwP8B38rxoxvOxFsAAAAASUVO
RK5CYII=">
<p style="top:32.6pt;left:56.7pt;line-height:8.0pt"><span style="font-family:TqgscwAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Martinez</span><span style="font-family:XdxhkwAdvTT7329fd89.I,serif;font-size:8.0pt;color:#131313"> et al. Stem Cell Research &amp; Therapy</span><span style="font-family:MyriadPro,serif;font-size:8.0pt;color:#131313">          (2020) 11:272 </span></p>
<p style="top:42.6pt;left:56.7pt;line-height:8.0pt"><span style="font-family:TqgscwAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">https://doi.org/10.1186/s13287-020-01764-x</span></p>


<p style="top:87.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">and effective [</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">8</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">,</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff"> 9</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">]. Currently, early phase clinical trials</span></p>
<p style="top:99.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">utilizing regenerative cells for CCHD and other pediatric</span></p>
<p style="top:111.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">heart conditions are ongoing.</span></p>
<p style="top:123.5pt;left:64.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">We conducted a systematic review and meta-analysis</span></p>
<p style="top:135.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">of pre-clinical and clinical studies to test the hypothesis</span></p>
<p style="top:147.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">that cell-based/derived therapies for congenital or ac-</span></p>
<p style="top:159.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">quired pediatric heart disease are safe and effective. In</span></p>
<p style="top:171.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">doing so, we hope to identify the variables that will have</span></p>
<p style="top:183.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">the greatest clinical impact and identify knowledge gaps</span></p>
<p style="top:195.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">that need to be addressed in future studies. Implications</span></p>
<p style="top:207.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">from this review may provide recommendations and</span></p>
<p style="top:219.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">evidence-based results for future human trials.</span></p>
<p style="top:243.1pt;left:56.7pt;line-height:10.3pt"><span style="font-family:QlgxmbAdvTTaf7f9f4f.B,serif;font-size:10.3pt;color:#131313">Methods</span></p>
<p style="top:255.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">The protocol for this review was submitted and regis-</span></p>
<p style="top:267.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">tered with PROSPERO international database of system-</span></p>
<p style="top:279.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">atic</span></p>
<p style="top:279.5pt;left:81.2pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">reviews</span></p>
<p style="top:279.5pt;left:121.3pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">and</span></p>
<p style="top:279.5pt;left:146.3pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">meta-analysis</span></p>
<p style="top:279.5pt;left:211.4pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">(Supplemental</span></p>
<p style="top:279.5pt;left:280.3pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">1</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">):</span></p>
<p style="top:291.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">registration number: CRD42019149559. Our methods</span></p>
<p style="top:303.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">adhere to the guidelines established by the Systematic</span></p>
<p style="top:315.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Review Centre for Laboratory Animal Experimentation</span></p>
<p style="top:327.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">(SYRCLE) and are described in Supplemental</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff"> 2</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">.</span></p>
<p style="top:352.0pt;left:56.7pt;line-height:9.2pt"><span style="font-family:HqrmbcAdvTT99c4c969,serif;font-size:9.2pt;color:#131313">Literature search</span></p>
<p style="top:363.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Literature search was performed using PUBMED, Sco-</span></p>
<p style="top:375.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">pus, ScienceDirect, and Web of Science through Sep-</span></p>
<p style="top:387.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">tember 3, 2019. Search terms included synonyms for</span></p>
<p style="top:399.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:DljwryAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x201c;</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">stem cell,</span><span style="font-family:DljwryAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x201d; &#x201c;</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">regenerative therapy,</span><span style="font-family:DljwryAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x201d;</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> and</span><span style="font-family:DljwryAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313"> &#x201c;</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">congenital heart</span></p>
<p style="top:411.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">disease</span><span style="font-family:DljwryAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x201d;</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> (full search terms available in Supplemental</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff"> 3</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">).</span></p>
<p style="top:423.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Restrictions to the search were not placed on dates or</span></p>
<p style="top:435.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">languages. Reference lists of relevant reviews and in-</span></p>
<p style="top:447.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">cluded studies were examined.</span></p>
<p style="top:459.5pt;left:64.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">After removal of duplicates, papers were screened by</span></p>
<p style="top:471.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">title and abstract and then evaluated for eligibility by</span></p>
<p style="top:483.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">full-text review performed by two independent investiga-</span></p>
<p style="top:495.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">tors (JM, SZ). Differences of opinion in either phase</span></p>
<p style="top:507.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">were resolved by a third investigator (AM). Individual</span></p>
<p style="top:519.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">searches of reference lists of included studies were per-</span></p>
<p style="top:531.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">formed in an attempt to obtain additional studies for</span></p>
<p style="top:543.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">inclusion.</span></p>
<p style="top:568.0pt;left:56.7pt;line-height:9.2pt"><span style="font-family:HqrmbcAdvTT99c4c969,serif;font-size:9.2pt;color:#131313">Inclusion and exclusion criteria</span></p>
<p style="top:579.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Interventional and observational human studies asses-</span></p>
<p style="top:591.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">sing the safety and efficacy of CBT in congenital/</span></p>
<p style="top:603.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">pediatric heart disease were included. We defined cell-</span></p>
<p style="top:615.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">based therapies to include the following: mesenchymal</span></p>
<p style="top:627.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">stromal cells, embryonic cells, multipotent cells, indu-</span></p>
<p style="top:639.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">cible pluripotent cells, progenitor cells, hematopoietic</span></p>
<p style="top:651.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">cells, umbilical cord blood cells, c-kit+ cells, and cell de-</span></p>
<p style="top:663.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">rived as the secretome, exosomes, microRNA, microvesi-</span></p>
<p style="top:675.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">cles, and extracellular vesicles. Due to the paucity of</span></p>
<p style="top:687.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">human studies evaluating stem cell use in congenital</span></p>
<p style="top:699.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">heart disease, case reports were included. Studies includ-</span></p>
<p style="top:711.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">ing adult patients with a history of congenital heart dis-</span></p>
<p style="top:723.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">ease (i.e., hypoplastic left heart syndrome (HLHS))</span></p>
<p style="top:87.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">receiving CBT were included, whereas studies describing</span></p>
<p style="top:99.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">use of regenerative therapies in adult patients with other</span></p>
<p style="top:111.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">cardiac</span></p>
<p style="top:111.5pt;left:342.6pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">illnesses</span></p>
<p style="top:111.5pt;left:384.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">(i.e.,</span></p>
<p style="top:111.5pt;left:410.1pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">myocardial</span></p>
<p style="top:111.5pt;left:463.9pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">infarctions)</span></p>
<p style="top:111.5pt;left:519.3pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">were</span></p>
<p style="top:123.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">excluded.</span></p>
<p style="top:135.5pt;left:312.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Pre-clinical studies were included if they reported the</span></p>
<p style="top:147.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">effect of CBT on validated in vivo animal models of con-</span></p>
<p style="top:159.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">genital heart disease (e.g., RV overload). The uses of</span></p>
<p style="top:171.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">CBT were included regardless of dosage, timing, fre-</span></p>
<p style="top:183.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">quency, and source. Animal models of adult heart dis-</span></p>
<p style="top:195.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">ease (myocardial infarction/ischemia) or healthy hearts</span></p>
<p style="top:207.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">were excluded.</span></p>
<p style="top:232.0pt;left:304.7pt;line-height:9.2pt"><span style="font-family:HqrmbcAdvTT99c4c969,serif;font-size:9.2pt;color:#131313">Primary endpoints</span></p>
<p style="top:243.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Our primary endpoints were safety and efficacy of cell-</span></p>
<p style="top:255.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">based/derived therapies in pre-clinical or clinical studies</span></p>
<p style="top:267.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">of both congenital and pediatric heart disease. Safety</span></p>
<p style="top:279.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">was defined as either mortality or the occurrence of ad-</span></p>
<p style="top:291.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">verse events (e.g., fever, rash, infection, hemodynamic in-</span></p>
<p style="top:303.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">stability, arrhythmia) associated with administration of</span></p>
<p style="top:315.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">CBT. Efficacy included measures of cardiac function:</span></p>
<p style="top:327.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">right ventricular ejection fraction, left ventricular ejec-</span></p>
<p style="top:339.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">tion fraction (RVEF, LVEF), end diastolic or end systolic</span></p>
<p style="top:351.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">volumes (EDV, ESV), fractional area change (FAC), frac-</span></p>
<p style="top:363.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">tional shortening (FS), and tricuspid annular plane sys-</span></p>
<p style="top:375.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">tolic excursion (TAPSE).</span></p>
<p style="top:400.0pt;left:304.7pt;line-height:9.2pt"><span style="font-family:HqrmbcAdvTT99c4c969,serif;font-size:9.2pt;color:#131313">Data extraction</span></p>
<p style="top:411.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Data was collected independently by two investigators</span></p>
<p style="top:423.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">(JM, SZ) and compared for accuracy. A third investigator</span></p>
<p style="top:435.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">(AM) assisted in resolution of difference of opinion. Ex-</span></p>
<p style="top:447.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">tracted data included general study design (disease</span></p>
<p style="top:459.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">model, clinical trial phase, objective, sample size, inclu-</span></p>
<p style="top:471.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">sion/exclusion criteria), animal characteristics (species,</span></p>
<p style="top:483.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">age, gender, immune status), intervention characteristics</span></p>
<p style="top:495.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">(cell type, tissue source, dose, delivery, timing, fre-</span></p>
<p style="top:507.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">quency), and bibliographical information (author, year,</span></p>
<p style="top:519.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">funding, title, language, contact author email, journal)</span></p>
<p style="top:531.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">along with any measures related to our primary outcome</span></p>
<p style="top:543.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">as defined above. Study data was obtained from text,</span></p>
<p style="top:555.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">graphs, and plots. WebPlot digitizer was used to collect</span></p>
<p style="top:567.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">values from figures when not explicitly stated in the text.</span></p>
<p style="top:579.5pt;left:312.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">For all studies where dosages were not reported in a</span></p>
<p style="top:591.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">cells/kg basis, the mean weight reported was used to cal-</span></p>
<p style="top:603.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">culate a mean dose of cells/kg. When an absolute cell</span></p>
<p style="top:615.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">count was provided, the mean weight (if present) was</span></p>
<p style="top:627.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">used to obtain a cells/kg dose. When two separate dos-</span></p>
<p style="top:639.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">ages were reported, mean dose/kg were obtained. When</span></p>
<p style="top:651.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">no weight was reported, absolute cell number was used.</span></p>
<p style="top:663.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Such cases are denoted by an asterisk in Table</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff"> 1</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">.</span></p>
<p style="top:675.5pt;left:312.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Additional cell-based/derived characteristics obtained</span></p>
<p style="top:687.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">included passage number, whether cells were self-</span></p>
<p style="top:699.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">isolated or purchased along with any positive surface</span></p>
<p style="top:711.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">markers noted in each study. When a study did not ex-</span></p>
<p style="top:723.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">plicitly use a variable (e.g., EF), but measurements were</span></p>
<p style="top:32.6pt;left:56.7pt;line-height:8.0pt"><span style="font-family:TqgscwAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Martinez</span><span style="font-family:XdxhkwAdvTT7329fd89.I,serif;font-size:8.0pt;color:#131313"> et al. Stem Cell Research &amp; Therapy</span><span style="font-family:MyriadPro,serif;font-size:8.0pt;color:#131313">          (2020) 11:272 </span></p>
<p style="top:32.6pt;left:496.1pt;line-height:8.0pt"><span style="font-family:TqgscwAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Page 2 of 13</span></p>


<p style="top:87.9pt;left:56.7pt;line-height:9.0pt"><span style="font-family:QlgxmbAdvTTaf7f9f4f.B,serif;font-size:9.0pt;color:#131313">Table 1</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:9.0pt;color:#131313"> Overview of pre-clinical study details</span></p>
<p style="top:101.8pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Author</span></p>
<p style="top:110.8pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">(year)</span></p>
<p style="top:101.8pt;left:98.8pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Study design</span></p>
<p style="top:101.8pt;left:162.2pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Animal characteristics</span></p>
<p style="top:101.8pt;left:302.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Intervention characteristics</span></p>
<p style="top:101.8pt;left:444.1pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Outcome measures</span></p>
<p style="top:115.0pt;left:98.8pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Disease model</span></p>
<p style="top:115.0pt;left:162.2pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Species</span></p>
<p style="top:115.0pt;left:200.8pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Age</span></p>
<p style="top:115.0pt;left:231.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Immunosuppression Cell type; source</span></p>
<p style="top:124.0pt;left:302.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">(origin)</span></p>
<p style="top:115.0pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Total dose (cells/</span></p>
<p style="top:124.0pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">kg), route, timing</span></p>
<p style="top:133.0pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">of delivery,</span></p>
<p style="top:142.0pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">frequency</span></p>
<p style="top:115.0pt;left:444.1pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Timing of</span></p>
<p style="top:124.0pt;left:444.1pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">assessment</span></p>
<p style="top:133.0pt;left:444.1pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">relative to</span></p>
<p style="top:142.0pt;left:444.1pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">injury</span></p>
<p style="top:115.0pt;left:493.0pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Ventricular</span></p>
<p style="top:124.0pt;left:493.0pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">function</span></p>
<p style="top:133.0pt;left:493.0pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">mode of</span></p>
<p style="top:142.0pt;left:493.0pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">assessment</span></p>
<p style="top:155.1pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Agarwal</span></p>
<p style="top:164.1pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">et al. [</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt;color:#0000ff">10</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:155.1pt;left:98.8pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">RVHF</span></p>
<p style="top:155.1pt;left:162.2pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Crl:NIH-</span></p>
<p style="top:164.1pt;left:162.2pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Foxn1rnu</span></p>
<p style="top:173.1pt;left:162.2pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">rats</span></p>
<p style="top:155.1pt;left:200.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">5</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">6</span></p>
<p style="top:164.1pt;left:200.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">weeks</span></p>
<p style="top:155.1pt;left:231.2pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Athymic</span></p>
<p style="top:155.1pt;left:302.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Cardiac progenitor</span></p>
<p style="top:164.1pt;left:302.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">(xenogeneic)</span></p>
<p style="top:155.1pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">6.6 &#xd7; 10</span><sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:5.7pt">6</span></sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">;</span></p>
<p style="top:164.1pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">intramyocardial;</span></p>
<p style="top:173.1pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">2 weeks; once</span></p>
<p style="top:155.1pt;left:444.1pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Two weeks</span></p>
<p style="top:164.1pt;left:444.1pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">and 1 month</span></p>
<p style="top:155.1pt;left:493.0pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Echo</span></p>
<p style="top:187.1pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Albertario</span></p>
<p style="top:196.1pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">et al .[</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt;color:#0000ff">11</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:187.1pt;left:98.8pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">RVHF</span></p>
<p style="top:187.1pt;left:162.2pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Landrace</span></p>
<p style="top:196.1pt;left:162.2pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">pigs</span></p>
<p style="top:187.1pt;left:200.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">DNR</span></p>
<p style="top:187.1pt;left:231.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">DNR</span></p>
<p style="top:187.1pt;left:302.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Thymic (xenogeneic)</span></p>
<p style="top:187.1pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">5.0 &#xd7; 10</span><sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:5.7pt">5 a</span></sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">; patch/</span></p>
<p style="top:196.1pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">graft; DNR; once</span></p>
<p style="top:187.1pt;left:444.1pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">DNR</span></p>
<p style="top:187.1pt;left:493.0pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Echo, cardiac</span></p>
<p style="top:196.1pt;left:493.0pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">MRI</span></p>
<p style="top:210.1pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Borenstein</span></p>
<p style="top:219.1pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">et al.</span></p>
<p style="top:210.1pt;left:98.8pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">RVHF</span></p>
<p style="top:210.1pt;left:162.2pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Ile de</span></p>
<p style="top:219.1pt;left:162.2pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">France</span></p>
<p style="top:228.1pt;left:162.2pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">rams</span></p>
<p style="top:210.1pt;left:200.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">4</span></p>
<p style="top:219.1pt;left:200.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">months</span></p>
<p style="top:210.1pt;left:231.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Dexamethasone</span></p>
<p style="top:210.1pt;left:302.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Skeletal muscle</span></p>
<p style="top:219.1pt;left:302.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">(autologous)</span></p>
<p style="top:210.1pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">4.3 &#xd7; 10</span><sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:5.7pt">5</span></sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">;</span></p>
<p style="top:219.1pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">intramyocardial;</span></p>
<p style="top:228.1pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">3 h; once</span></p>
<p style="top:210.1pt;left:444.1pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Day 0 and</span></p>
<p style="top:219.1pt;left:444.1pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">day 60</span></p>
<p style="top:210.1pt;left:493.0pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Cath</span></p>
<p style="top:242.1pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Brizard</span></p>
<p style="top:251.2pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">et al. [</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt;color:#0000ff">12</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:242.1pt;left:98.8pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Cardiopulmonary</span></p>
<p style="top:251.2pt;left:98.8pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">bypass</span></p>
<p style="top:242.1pt;left:162.2pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Border-</span></p>
<p style="top:251.2pt;left:162.2pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Leicester</span></p>
<p style="top:260.1pt;left:162.2pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">lamb</span></p>
<p style="top:242.1pt;left:200.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">5</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">7</span></p>
<p style="top:251.2pt;left:200.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">days</span></p>
<p style="top:242.1pt;left:231.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">DNR</span></p>
<p style="top:242.1pt;left:302.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Umbilical cord</span></p>
<p style="top:251.2pt;left:302.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">blood (xenogeneic)</span></p>
<p style="top:242.1pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">8.0 &#xd7; 10</span><sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:5.7pt">6</span></sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">;</span></p>
<p style="top:251.2pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">intracoronary;</span></p>
<p style="top:260.1pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">intraoperative;</span></p>
<p style="top:269.1pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">once</span></p>
<p style="top:242.1pt;left:444.1pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">DNR</span></p>
<p style="top:242.1pt;left:493.0pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Cath</span></p>
<p style="top:283.1pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Cao et al.</span></p>
<p style="top:283.1pt;left:98.8pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">RVHF</span></p>
<p style="top:283.1pt;left:162.2pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">New</span></p>
<p style="top:292.1pt;left:162.2pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Zealand</span></p>
<p style="top:301.2pt;left:162.2pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">white</span></p>
<p style="top:310.1pt;left:162.2pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">rabbits</span></p>
<p style="top:283.1pt;left:200.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">1</span></p>
<p style="top:292.1pt;left:200.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">month</span></p>
<p style="top:283.1pt;left:231.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">DNR</span></p>
<p style="top:283.1pt;left:302.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Bone marrow</span></p>
<p style="top:292.1pt;left:302.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">(autologous)</span></p>
<p style="top:283.1pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">1.9 &#xd7; 10</span><sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:5.7pt">7</span></sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">;</span></p>
<p style="top:292.1pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">intravenous;</span></p>
<p style="top:301.2pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">3 months; once</span></p>
<p style="top:283.1pt;left:444.1pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Two weeks</span></p>
<p style="top:283.1pt;left:493.0pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Echo, Cath</span></p>
<p style="top:324.1pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Chery et al. RVHF</span></p>
<p style="top:324.1pt;left:162.2pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">RNU</span></p>
<p style="top:333.1pt;left:162.2pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">nude rats</span></p>
<p style="top:324.1pt;left:200.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">DNR</span></p>
<p style="top:324.1pt;left:231.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">DNR</span></p>
<p style="top:324.1pt;left:302.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Thymic (xenogeneic)</span></p>
<p style="top:324.1pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">1.8 &#xd7; 10</span><sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:5.7pt">7</span></sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">; cell sheet;</span></p>
<p style="top:333.1pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">2 weeks; once</span></p>
<p style="top:324.1pt;left:444.1pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">DNR</span></p>
<p style="top:324.1pt;left:493.0pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Echo</span></p>
<p style="top:347.1pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Davies</span></p>
<p style="top:356.2pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">et al .[</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt;color:#0000ff">13</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:347.1pt;left:98.8pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">RVHF</span></p>
<p style="top:347.1pt;left:162.2pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Leicester</span></p>
<p style="top:356.2pt;left:162.2pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">sheep</span></p>
<p style="top:347.1pt;left:200.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">10 days</span></p>
<p style="top:347.1pt;left:231.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Cyclosporine</span></p>
<p style="top:347.1pt;left:302.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Umbilical cord</span></p>
<p style="top:356.2pt;left:302.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">blood (xenogeneic)</span></p>
<p style="top:347.1pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">7.0 &#xd7; 10</span><sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:5.7pt">5</span></sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">;</span></p>
<p style="top:356.2pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">epicardial; 30 min;</span></p>
<p style="top:365.1pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">once</span></p>
<p style="top:347.1pt;left:444.1pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">One month</span></p>
<p style="top:347.1pt;left:493.0pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Cath</span></p>
<p style="top:379.1pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Henning</span></p>
<p style="top:388.1pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">et al.</span></p>
<p style="top:379.1pt;left:98.8pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">DCM</span></p>
<p style="top:379.1pt;left:162.2pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">TO2</span></p>
<p style="top:388.1pt;left:162.2pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">hamsters</span></p>
<p style="top:379.1pt;left:200.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">1</span></p>
<p style="top:388.1pt;left:200.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">month</span></p>
<p style="top:379.1pt;left:231.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">DNR</span></p>
<p style="top:379.1pt;left:302.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Umbilical cord</span></p>
<p style="top:388.1pt;left:302.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">blood (xenogeneic)</span></p>
<p style="top:379.1pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">5.3 &#xd7; 10</span><sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:5.7pt">7</span></sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">;</span></p>
<p style="top:388.1pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">intramyocardial;</span></p>
<p style="top:397.1pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">1 month; once</span></p>
<p style="top:379.1pt;left:444.1pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Monthly, 1</span></p>
<p style="top:388.1pt;left:444.1pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">to 5 months</span></p>
<p style="top:379.1pt;left:493.0pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Echo</span></p>
<p style="top:411.1pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Lambert</span></p>
<p style="top:420.2pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">et al.</span></p>
<p style="top:411.1pt;left:98.8pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">RVHF</span></p>
<p style="top:411.1pt;left:162.2pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Landrace</span></p>
<p style="top:420.2pt;left:162.2pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">pigs</span></p>
<p style="top:411.1pt;left:200.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">2</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">3</span></p>
<p style="top:420.2pt;left:200.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">months</span></p>
<p style="top:411.1pt;left:231.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Tacrolimus</span></p>
<p style="top:411.1pt;left:302.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Cardiac progenitor</span></p>
<p style="top:420.2pt;left:302.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">(xenogeneic)</span></p>
<p style="top:411.1pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">4.7 &#xd7; 10</span><sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:5.7pt">5</span></sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">;</span></p>
<p style="top:420.2pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">intramyocardial;</span></p>
<p style="top:429.1pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">4 months; once</span></p>
<p style="top:411.1pt;left:444.1pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Four months</span></p>
<p style="top:420.2pt;left:444.1pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">and</span></p>
<p style="top:429.1pt;left:444.1pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">7 months</span></p>
<p style="top:411.1pt;left:493.0pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Cath</span></p>
<p style="top:443.1pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Liu et al.</span></p>
<p style="top:443.1pt;left:98.8pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">RVHF</span></p>
<p style="top:443.1pt;left:162.2pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Wistar</span></p>
<p style="top:452.1pt;left:162.2pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">lamb</span></p>
<p style="top:443.1pt;left:200.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">DNR</span></p>
<p style="top:443.1pt;left:231.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">DNR</span></p>
<p style="top:443.1pt;left:302.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Adipose</span></p>
<p style="top:452.1pt;left:302.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">(autologous)</span></p>
<p style="top:443.1pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">5.0 &#xd7; 10</span><sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:5.7pt">7</span></sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">;</span></p>
<p style="top:452.1pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">intravenous;</span></p>
<p style="top:461.1pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">3 months; once</span></p>
<p style="top:443.1pt;left:444.1pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">DNR</span></p>
<p style="top:443.1pt;left:493.0pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Echo, Cath</span></p>
<p style="top:475.1pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Nana-</span></p>
<p style="top:484.1pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Leventaki</span></p>
<p style="top:493.1pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">et al .[</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt;color:#0000ff">14</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">]</span></p>
<p style="top:475.1pt;left:98.8pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">AI</span></p>
<p style="top:475.1pt;left:162.2pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Lewis rats</span></p>
<p style="top:475.1pt;left:200.8pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">5</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">6</span></p>
<p style="top:484.1pt;left:200.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">weeks</span></p>
<p style="top:475.1pt;left:231.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">DNR</span></p>
<p style="top:475.1pt;left:302.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Cardiosphere</span></p>
<p style="top:484.1pt;left:302.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">derived (autologous)</span></p>
<p style="top:475.1pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">1.7 &#xd7; 10</span><sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:5.7pt">6 b</span></sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">;</span></p>
<p style="top:484.1pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">intracoronary;</span></p>
<p style="top:493.1pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">10 days; once</span></p>
<p style="top:475.1pt;left:444.1pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">One day,</span></p>
<p style="top:484.1pt;left:444.1pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">10 days,</span></p>
<p style="top:493.1pt;left:444.1pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">1 month</span></p>
<p style="top:475.1pt;left:493.0pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Echo</span></p>
<p style="top:507.1pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Schmuck</span></p>
<p style="top:516.1pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">et al.</span></p>
<p style="top:507.1pt;left:98.8pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">RVHF</span></p>
<p style="top:507.1pt;left:162.2pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Sprague</span></p>
<p style="top:516.1pt;left:162.2pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Dawley</span></p>
<p style="top:525.2pt;left:162.2pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">rats</span></p>
<p style="top:507.1pt;left:200.8pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">5</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">6</span></p>
<p style="top:516.1pt;left:200.8pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">weeks</span></p>
<p style="top:507.1pt;left:231.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">DNR</span></p>
<p style="top:507.1pt;left:302.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Cardiac fibroblasts</span></p>
<p style="top:516.1pt;left:302.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">(xenogeneic)</span></p>
<p style="top:507.1pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">2.0 &#xd7; 10</span><sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:5.7pt">6 a</span></sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">;</span></p>
<p style="top:516.1pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">bioscaffold</span></p>
<p style="top:525.2pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">implanted into RV;</span></p>
<p style="top:534.1pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">3 weeks; once</span></p>
<p style="top:507.1pt;left:444.1pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Baseline,</span></p>
<p style="top:516.1pt;left:444.1pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">3 weeks and</span></p>
<p style="top:525.2pt;left:444.1pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">6 weeks</span></p>
<p style="top:507.1pt;left:493.0pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Echo, Cath</span></p>
<p style="top:548.1pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Sugiura</span></p>
<p style="top:557.1pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">et al.</span></p>
<p style="top:566.1pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">(2016)</span></p>
<p style="top:548.1pt;left:98.8pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">RVHF</span></p>
<p style="top:548.1pt;left:162.2pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Nude</span></p>
<p style="top:557.1pt;left:162.2pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">athymic</span></p>
<p style="top:566.1pt;left:162.2pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">rats</span></p>
<p style="top:548.1pt;left:200.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">DNR</span></p>
<p style="top:548.1pt;left:231.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Athymic</span></p>
<p style="top:548.1pt;left:302.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Cardiac (xenogeneic) 2.0 &#xd7; 10</span><sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:5.7pt">5 a</span></sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">; patch;</span></p>
<p style="top:557.1pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">DNR; once</span></p>
<p style="top:548.1pt;left:444.1pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Two and</span></p>
<p style="top:557.1pt;left:444.1pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">4 months</span></p>
<p style="top:548.1pt;left:493.0pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Echo</span></p>
<p style="top:580.1pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Trac et al.</span></p>
<p style="top:580.1pt;left:98.8pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">RVHF</span></p>
<p style="top:580.1pt;left:162.2pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Crl:NIH-</span></p>
<p style="top:589.2pt;left:162.2pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Foxn1rnu</span></p>
<p style="top:598.1pt;left:162.2pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">rats</span></p>
<p style="top:580.1pt;left:200.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">6</span></p>
<p style="top:589.2pt;left:200.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">weeks</span></p>
<p style="top:580.1pt;left:231.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Athymic</span></p>
<p style="top:580.1pt;left:302.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Cardiac progenitor</span></p>
<p style="top:589.2pt;left:302.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">(xenogeneic)</span></p>
<p style="top:580.1pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">3.0 &#xd7; 10</span><sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:5.7pt">6</span></sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">;</span></p>
<p style="top:589.2pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">intramyocardial;</span></p>
<p style="top:598.1pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">2 weeks; once</span></p>
<p style="top:580.1pt;left:444.1pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Weekly for</span></p>
<p style="top:589.2pt;left:444.1pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">4 weeks</span></p>
<p style="top:580.1pt;left:493.0pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Echo</span></p>
<p style="top:612.1pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Umar et al.</span></p>
<p style="top:621.1pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">(2009)</span></p>
<p style="top:612.1pt;left:98.8pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">RVHF</span></p>
<p style="top:612.1pt;left:162.2pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Wistar rat</span></p>
<p style="top:612.1pt;left:200.8pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">8</span></p>
<p style="top:621.1pt;left:200.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">weeks</span></p>
<p style="top:612.1pt;left:231.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">DNR</span></p>
<p style="top:612.1pt;left:302.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Bone marrow-</span></p>
<p style="top:621.1pt;left:302.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">derived mesenchy-</span></p>
<p style="top:630.1pt;left:302.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">mal stem cells</span></p>
<p style="top:639.1pt;left:302.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">(autologous)</span></p>
<p style="top:612.1pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">4.4 &#xd7; 10</span><sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:5.7pt">3</span></sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">;</span></p>
<p style="top:621.1pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">intravenous; 2</span></p>
<p style="top:630.1pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">weeks; once</span></p>
<p style="top:612.1pt;left:444.1pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Two weeks</span></p>
<p style="top:612.1pt;left:493.0pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Cath</span></p>
<p style="top:653.1pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Wehman</span></p>
<p style="top:662.1pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">et al.</span></p>
<p style="top:671.1pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">(2016)</span></p>
<p style="top:653.1pt;left:98.8pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">RVHF</span></p>
<p style="top:653.1pt;left:162.2pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Yorkshire</span></p>
<p style="top:662.1pt;left:162.2pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">swine</span></p>
<p style="top:653.1pt;left:200.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">2</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">3</span></p>
<p style="top:662.1pt;left:200.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">weeks</span></p>
<p style="top:653.1pt;left:231.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Cyclosporine and</span></p>
<p style="top:662.1pt;left:231.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">methylprednisolone</span></p>
<p style="top:653.1pt;left:302.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Bone marrow</span></p>
<p style="top:662.1pt;left:302.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">(xenogeneic)</span></p>
<p style="top:653.1pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">1.25 &#xd7; 10</span><sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:5.7pt">5</span></sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">;</span></p>
<p style="top:662.1pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">intramyocardial;</span></p>
<p style="top:671.1pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">30 min; once</span></p>
<p style="top:653.1pt;left:444.1pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Four months</span></p>
<p style="top:653.1pt;left:493.0pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Echo</span></p>
<p style="top:685.1pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Wehman</span></p>
<p style="top:694.2pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">et al.</span></p>
<p style="top:703.1pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">(2017)</span></p>
<p style="top:685.1pt;left:98.8pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">RVHF</span></p>
<p style="top:685.1pt;left:162.2pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Yorkshire</span></p>
<p style="top:694.2pt;left:162.2pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">swine</span></p>
<p style="top:685.1pt;left:200.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">2</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">3</span></p>
<p style="top:694.2pt;left:200.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">weeks</span></p>
<p style="top:685.1pt;left:231.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Cyclosporine and</span></p>
<p style="top:694.2pt;left:231.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">methylprednisolone</span></p>
<p style="top:685.1pt;left:302.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Cardiac progenitor</span></p>
<p style="top:694.2pt;left:302.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">(xenogeneic)</span></p>
<p style="top:685.1pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">1.25 &#xd7; 10</span><sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:5.7pt">5</span></sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">;</span></p>
<p style="top:694.2pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">intramyocardial;</span></p>
<p style="top:703.1pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">morning of</span></p>
<p style="top:712.1pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">isolation; once</span></p>
<p style="top:685.1pt;left:444.1pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">One day and</span></p>
<p style="top:694.2pt;left:444.1pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">1 month</span></p>
<p style="top:685.1pt;left:493.0pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Echo</span></p>
<p style="top:32.6pt;left:56.7pt;line-height:8.0pt"><span style="font-family:TqgscwAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Martinez</span><span style="font-family:XdxhkwAdvTT7329fd89.I,serif;font-size:8.0pt;color:#131313"> et al. Stem Cell Research &amp; Therapy</span><span style="font-family:MyriadPro,serif;font-size:8.0pt;color:#131313">          (2020) 11:272 </span></p>
<p style="top:32.6pt;left:496.1pt;line-height:8.0pt"><span style="font-family:TqgscwAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Page 3 of 13</span></p>


<p style="top:231.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">provided such that it could be calculated (i.e., EDV, SV),</span></p>
<p style="top:243.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">these measurements were used to obtain variable of</span></p>
<p style="top:255.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">interest using the equation EF = SV/EDV [</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">15</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">].</span></p>
<p style="top:286.0pt;left:56.7pt;line-height:9.2pt"><span style="font-family:HqrmbcAdvTT99c4c969,serif;font-size:9.2pt;color:#131313">Data analysis</span></p>
<p style="top:297.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Meta-analysis was conducted using a random effects</span></p>
<p style="top:309.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">model. The estimated efficacy of regenerative therapies</span></p>
<p style="top:321.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">was determined using mean differences (MD) or stan-</span></p>
<p style="top:333.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">dardized mean differences (SMD) with a 95% confidence</span></p>
<p style="top:345.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">interval (CI) [</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">7</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">]. SMD was used when studies reported</span></p>
<p style="top:357.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">the same outcome but reported in a different manner</span></p>
<p style="top:369.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">(e.g., MRI, echocardiogram, cardiac catheterization). For</span></p>
<p style="top:381.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">studies</span></p>
<p style="top:381.5pt;left:93.1pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">that</span></p>
<p style="top:381.5pt;left:117.3pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">described</span></p>
<p style="top:381.5pt;left:164.2pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">greater</span></p>
<p style="top:381.5pt;left:200.8pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">than</span></p>
<p style="top:381.5pt;left:227.3pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">two</span></p>
<p style="top:381.5pt;left:250.6pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">treatment</span></p>
<p style="top:393.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">groups, only the cell-based group and control were ana-</span></p>
<p style="top:405.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">lyzed. Studies that did not include a control arm were</span></p>
<p style="top:417.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">described qualitatively.</span></p>
<p style="top:429.5pt;left:64.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Subgroup analysis was performed to assess for variabil-</span></p>
<p style="top:441.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">ity in safety and efficacy of CBT by route, dose, timing,</span></p>
<p style="top:453.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">source, and disease model. If multiple assessments of</span></p>
<p style="top:465.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">cardiac function were made in the article, they were</span></p>
<p style="top:477.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">regarded as separate experiments/datapoints. Cardiac</span></p>
<p style="top:489.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">variables were obtained at the time of induction of the</span></p>
<p style="top:501.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">cardiac model in animals and any subsequent measure-</span></p>
<p style="top:513.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">ments. In humans, baseline functional measures were</span></p>
<p style="top:525.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">compared to all timepoints after administration of CBT.</span></p>
<p style="top:537.5pt;left:64.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Statistical heterogeneity between studies was assessed</span></p>
<p style="top:549.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">via</span><span style="font-family:PrrxjsAdvTT8861b38f.I,serif;font-size:9.8pt;color:#131313"> I</span><sup><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:6.9pt;color:#131313">2</span></sup><sup><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> </span></sup><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">with a value &gt; 50% suggesting heterogeneity. Sub-</span></p>
<p style="top:561.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">group analysis was performed to evaluate for potential</span></p>
<p style="top:573.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">sources of heterogeneity [</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">7</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">]. Meta-analysis was con-</span></p>
<p style="top:585.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">ducted in R using the dmetar package [</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">16</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">]. All statistical</span></p>
<p style="top:597.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">tests were two-sided, and the difference was deemed sig-</span></p>
<p style="top:609.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">nificant for a</span><span style="font-family:PrrxjsAdvTT8861b38f.I,serif;font-size:9.8pt;color:#131313"> p</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> value &lt; 0.05.</span></p>
<p style="top:640.0pt;left:56.7pt;line-height:9.2pt"><span style="font-family:HqrmbcAdvTT99c4c969,serif;font-size:9.2pt;color:#131313">Risk of bias</span></p>
<p style="top:651.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">All studies were assessed for bias by two independent re-</span></p>
<p style="top:663.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">viewers (JM, SZ). For animal studies, the SYRCLE risk of</span></p>
<p style="top:675.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">bias assessment tool was used [</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">17</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">], while ROBINS-I risk</span></p>
<p style="top:687.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">of bias was used for randomized/non-randomized con-</span></p>
<p style="top:699.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">trol trials [</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">18</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">,</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff"> 19</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">]. Publication bias assessed through the</span></p>
<p style="top:711.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">use of funnel plots and Egger</span><span style="font-family:DljwryAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2019;</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">s regression analysis. Fun-</span></p>
<p style="top:723.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">nel plots were visually assessed for asymmetry. For</span></p>
<p style="top:231.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Egger</span><span style="font-family:DljwryAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2019;</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">s test,</span><span style="font-family:PrrxjsAdvTT8861b38f.I,serif;font-size:9.8pt;color:#131313"> p</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> &lt; 0.05 was considered significant to con-</span></p>
<p style="top:243.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">firm the presence of a small study size.</span></p>
<p style="top:267.1pt;left:304.7pt;line-height:10.3pt"><span style="font-family:QlgxmbAdvTTaf7f9f4f.B,serif;font-size:10.3pt;color:#131313">Results</span></p>
<p style="top:279.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">We identified 14,179 papers that met our broad inclu-</span></p>
<p style="top:291.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">sion criteria in four databases. Ninety-six studies were</span></p>
<p style="top:303.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">selected for abstract/summary review; 55 studies were</span></p>
<p style="top:315.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">chosen for full text/detailed review. After thorough</span></p>
<p style="top:327.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">evaluation, a total of 31 studies were included in this re-</span></p>
<p style="top:339.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">view (complete list provided in Supplemental</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff"> 4</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">), refer to</span></p>
<p style="top:351.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Fig.</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff"> 1</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> for details and Supplemental</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff"> 5</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> for PRISMA check-</span></p>
<p style="top:363.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">list [</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">20</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">].</span></p>
<p style="top:388.0pt;left:304.7pt;line-height:9.2pt"><span style="font-family:HqrmbcAdvTT99c4c969,serif;font-size:9.2pt;color:#131313">Pre-clinical results</span></p>
<p style="top:400.0pt;left:304.7pt;line-height:9.2pt"><span style="font-family:QrkhyfAdvTT83913201.I,serif;font-size:9.2pt;color:#131313">Study characteristics</span></p>
<p style="top:411.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Eighteen of the included studies were animal (</span><span style="font-family:PrrxjsAdvTT8861b38f.I,serif;font-size:9.8pt;color:#131313">n</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> = 386).</span></p>
<p style="top:423.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">The model most commonly induced was right ventricu-</span></p>
<p style="top:435.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">lar</span></p>
<p style="top:435.5pt;left:323.5pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">heart</span></p>
<p style="top:435.5pt;left:352.6pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">failure</span></p>
<p style="top:435.5pt;left:386.5pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">(RVHF)</span></p>
<p style="top:435.5pt;left:426.4pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">(</span><span style="font-family:PrrxjsAdvTT8861b38f.I,serif;font-size:9.8pt;color:#131313">n</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> = 307,</span></p>
<p style="top:435.5pt;left:469.5pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">80%),</span></p>
<p style="top:435.5pt;left:499.6pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">with</span></p>
<p style="top:435.5pt;left:525.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">the</span></p>
<p style="top:447.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">remaining studies modeling dilated cardiomyopathy (</span><span style="font-family:PrrxjsAdvTT8861b38f.I,serif;font-size:9.8pt;color:#131313">n</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> =</span></p>
<p style="top:459.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">45), autoimmune myocarditis (</span><span style="font-family:PrrxjsAdvTT8861b38f.I,serif;font-size:9.8pt;color:#131313">n</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> = 22), and cardiopulmo-</span></p>
<p style="top:471.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">nary bypass (</span><span style="font-family:PrrxjsAdvTT8861b38f.I,serif;font-size:9.8pt;color:#131313">n</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> = 12). There was a near-equal distribution</span></p>
<p style="top:483.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">of small (55%) and large animals (45%). Ninety-four per-</span></p>
<p style="top:495.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">cent of studies reported our primary outcomes (safety</span></p>
<p style="top:507.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">and/or efficacy). Study details are described in Table</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff"> 1</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">.</span></p>
<p style="top:532.0pt;left:304.7pt;line-height:9.2pt"><span style="font-family:QrkhyfAdvTT83913201.I,serif;font-size:9.2pt;color:#131313">Intervention characteristics</span></p>
<p style="top:543.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">While our search included both cell-based and cell-</span></p>
<p style="top:555.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">derived therapies, zero studies utilized cell-derived ther-</span></p>
<p style="top:567.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">apies.</span></p>
<p style="top:567.5pt;left:337.4pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">The</span></p>
<p style="top:567.5pt;left:363.8pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">majority</span></p>
<p style="top:567.5pt;left:407.9pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">of</span></p>
<p style="top:567.5pt;left:426.0pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">studies</span></p>
<p style="top:567.5pt;left:464.4pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">introduced</span></p>
<p style="top:567.5pt;left:519.0pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">non-</span></p>
<p style="top:579.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">autologous cell sources (</span><span style="font-family:PrrxjsAdvTT8861b38f.I,serif;font-size:9.8pt;color:#131313">n</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> = 12, 67%). Tissue source of</span></p>
<p style="top:591.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">cells varied with cardiac and umbilical cord blood com-</span></p>
<p style="top:603.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">prising most studies (</span><span style="font-family:PrrxjsAdvTT8861b38f.I,serif;font-size:9.8pt;color:#131313">n</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> = 11, 61%). Intravenous (</span><span style="font-family:PrrxjsAdvTT8861b38f.I,serif;font-size:9.8pt;color:#131313">n</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> = 140)</span></p>
<p style="top:615.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">and intramyocardial injection (</span><span style="font-family:PrrxjsAdvTT8861b38f.I,serif;font-size:9.8pt;color:#131313">n</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> = 135) were the most</span></p>
<p style="top:627.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">frequent routes of cell delivery with a dose ranging from</span></p>
<p style="top:639.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">4.4 &#xd7; 10</span><sup><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:6.9pt;color:#131313">3</span></sup><sup><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> </span></sup><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">cells/kg to 5.3 &#xd7; 10</span><sup><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:6.9pt;color:#131313">7</span></sup><sup><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> </span></sup><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">cells/kg. A summary of</span></p>
<p style="top:651.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">study</span></p>
<p style="top:651.5pt;left:336.2pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">characteristics</span></p>
<p style="top:651.5pt;left:403.8pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">is</span></p>
<p style="top:651.5pt;left:419.8pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">provided</span></p>
<p style="top:651.5pt;left:465.2pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">in</span></p>
<p style="top:651.5pt;left:482.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Supplemental</span></p>
<p style="top:663.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Table</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff"> 1</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">.</span></p>
<p style="top:688.0pt;left:304.7pt;line-height:9.2pt"><span style="font-family:HqrmbcAdvTT99c4c969,serif;font-size:9.2pt;color:#131313">Cell-based/derived therapies are safe in animals</span></p>
<p style="top:700.0pt;left:304.7pt;line-height:9.2pt"><span style="font-family:QrkhyfAdvTT83913201.I,serif;font-size:9.2pt;color:#131313">Adverse events</span></p>
<p style="top:711.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Overall, there were no difference between CBT (16/409)</span></p>
<p style="top:723.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">and control groups (19/418) [Peto OR 0.89; 95% CI</span></p>
<p style="top:87.9pt;left:56.7pt;line-height:9.0pt"><span style="font-family:QlgxmbAdvTTaf7f9f4f.B,serif;font-size:9.0pt">Table 1</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:9.0pt"> Overview of pre-clinical study details</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:9.0pt"> (Continued)</span></p>
<p style="top:101.8pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Author</span></p>
<p style="top:110.8pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">(year)</span></p>
<p style="top:101.8pt;left:98.8pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Study design</span></p>
<p style="top:101.8pt;left:162.2pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Animal characteristics</span></p>
<p style="top:101.8pt;left:302.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Intervention characteristics</span></p>
<p style="top:101.8pt;left:444.1pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Outcome measures</span></p>
<p style="top:115.0pt;left:98.8pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Disease model</span></p>
<p style="top:115.0pt;left:162.2pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Species</span></p>
<p style="top:115.0pt;left:200.8pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Age</span></p>
<p style="top:115.0pt;left:231.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Immunosuppression Cell type; source</span></p>
<p style="top:124.0pt;left:302.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">(origin)</span></p>
<p style="top:115.0pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Total dose (cells/</span></p>
<p style="top:124.0pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">kg), route, timing</span></p>
<p style="top:133.0pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">of delivery,</span></p>
<p style="top:142.0pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">frequency</span></p>
<p style="top:115.0pt;left:444.1pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Timing of</span></p>
<p style="top:124.0pt;left:444.1pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">assessment</span></p>
<p style="top:133.0pt;left:444.1pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">relative to</span></p>
<p style="top:142.0pt;left:444.1pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">injury</span></p>
<p style="top:115.0pt;left:493.0pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Ventricular</span></p>
<p style="top:124.0pt;left:493.0pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">function</span></p>
<p style="top:133.0pt;left:493.0pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">mode of</span></p>
<p style="top:142.0pt;left:493.0pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">assessment</span></p>
<p style="top:155.1pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Yerebakan</span></p>
<p style="top:164.1pt;left:56.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">et al.</span></p>
<p style="top:155.1pt;left:98.8pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">RVHF</span></p>
<p style="top:155.1pt;left:162.2pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Domestic</span></p>
<p style="top:164.1pt;left:162.2pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">sheep</span></p>
<p style="top:155.1pt;left:200.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">4</span></p>
<p style="top:164.1pt;left:200.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">months</span></p>
<p style="top:155.1pt;left:231.2pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">DNR</span></p>
<p style="top:155.1pt;left:302.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Umbilical cord</span></p>
<p style="top:164.1pt;left:302.3pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">blood (autologous)</span></p>
<p style="top:155.1pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">2.0 &#xd7; 10</span><sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:5.7pt">6</span></sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">;</span></p>
<p style="top:164.1pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">intramyocardial;</span></p>
<p style="top:173.1pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">intraoperative;</span></p>
<p style="top:182.2pt;left:375.4pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">once</span></p>
<p style="top:155.1pt;left:444.1pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Six and</span></p>
<p style="top:164.1pt;left:444.1pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">12 weeks</span></p>
<p style="top:155.1pt;left:493.0pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt">Echo, Cath</span></p>
<p style="top:196.1pt;left:56.7pt;line-height:7.0pt"><span style="font-family:XdxhkwAdvTT7329fd89.I,serif;font-size:7.0pt">RVHF</span><span style="font-family:TqgscwAdvTTe45e47d2,serif;font-size:7.0pt"> right ventricular heart failure,</span><span style="font-family:XdxhkwAdvTT7329fd89.I,serif;font-size:7.0pt"> DCM</span><span style="font-family:TqgscwAdvTTe45e47d2,serif;font-size:7.0pt"> dilated cardiomyopathy,</span><span style="font-family:XdxhkwAdvTT7329fd89.I,serif;font-size:7.0pt"> AI</span><span style="font-family:TqgscwAdvTTe45e47d2,serif;font-size:7.0pt"> autoimmune myocarditis,</span><span style="font-family:XdxhkwAdvTT7329fd89.I,serif;font-size:7.0pt"> RV</span><span style="font-family:TqgscwAdvTTe45e47d2,serif;font-size:7.0pt"> right ventricle,</span><span style="font-family:XdxhkwAdvTT7329fd89.I,serif;font-size:7.0pt"> DNR</span><span style="font-family:TqgscwAdvTTe45e47d2,serif;font-size:7.0pt"> did not report</span></p>
<p style="top:203.1pt;left:56.7pt;line-height:4.9pt"><span style="font-family:TqgscwAdvTTe45e47d2,serif;font-size:4.9pt">a</span><span style="font-family:TqgscwAdvTTe45e47d2,serif;font-size:7.0pt">Absolute cell count</span></p>
<p style="top:211.6pt;left:56.7pt;line-height:4.9pt"><span style="font-family:TqgscwAdvTTe45e47d2,serif;font-size:4.9pt">b</span><span style="font-family:TqgscwAdvTTe45e47d2,serif;font-size:7.0pt">Dose obtained based on additional study cited within paper</span></p>
<p style="top:32.6pt;left:56.7pt;line-height:8.0pt"><span style="font-family:TqgscwAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Martinez</span><span style="font-family:XdxhkwAdvTT7329fd89.I,serif;font-size:8.0pt;color:#131313"> et al. Stem Cell Research &amp; Therapy</span><span style="font-family:MyriadPro,serif;font-size:8.0pt;color:#131313">          (2020) 11:272 </span></p>
<p style="top:32.6pt;left:496.1pt;line-height:8.0pt"><span style="font-family:TqgscwAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Page 4 of 13</span></p>


<p style="top:407.7pt;left:62.7pt;line-height:8.0pt"><span style="font-family:QlgxmbAdvTTaf7f9f4f.B,serif;font-size:8.0pt;color:#131313">Fig. 1</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> Flow diagram demonstrating study selection process</span></p>
<p style="top:708.7pt;left:62.7pt;line-height:8.0pt"><span style="font-family:QlgxmbAdvTTaf7f9f4f.B,serif;font-size:8.0pt;color:#131313">Fig. 2</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> Effect size of regenerative cells on animal mortality. Forest plot demonstrating OR and 95% CI. Cell based,</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:8.0pt;color:#131313"> n</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> = 136; Control,</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:8.0pt;color:#131313"> n</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> = 128;</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:8.0pt;color:#131313"> p</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> =</span></p>
<p style="top:718.7pt;left:62.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">0.94. Rightward of the line of null effect favors cell based group, leftward favors control</span></p>
<p style="top:32.6pt;left:56.7pt;line-height:8.0pt"><span style="font-family:TqgscwAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Martinez</span><span style="font-family:XdxhkwAdvTT7329fd89.I,serif;font-size:8.0pt;color:#131313"> et al. Stem Cell Research &amp; Therapy</span><span style="font-family:MyriadPro,serif;font-size:8.0pt;color:#131313">          (2020) 11:272 </span></p>
<p style="top:32.6pt;left:496.1pt;line-height:8.0pt"><span style="font-family:TqgscwAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Page 5 of 13</span></p>


<p style="top:87.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">(0.43, 1.83);</span><span style="font-family:PrrxjsAdvTT8861b38f.I,serif;font-size:9.8pt;color:#131313"> p</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> = 0.74]. Specifically, cardiac events were</span></p>
<p style="top:99.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">most frequently observed (21/147); the CBT group</span></p>
<p style="top:111.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">yielded 11% while the control group had 18% [Peto OR</span></p>
<p style="top:123.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">0.48; 95% CI (0.17, 1.33);</span><span style="font-family:PrrxjsAdvTT8861b38f.I,serif;font-size:9.8pt;color:#131313"> p</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> = 0.16]. The frequency of oc-</span></p>
<p style="top:135.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">currence of overall and system-specific adverse events is</span></p>
<p style="top:147.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">outlined in Supplemental Table</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff"> 3</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">. Adverse event spe-</span></p>
<p style="top:159.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">cifics are detailed in Supplemental Table</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff"> 2</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">.</span></p>
<p style="top:184.0pt;left:56.7pt;line-height:9.2pt"><span style="font-family:QrkhyfAdvTT83913201.I,serif;font-size:9.2pt;color:#131313">Mortality</span></p>
<p style="top:195.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">A total of thirteen studies reported mortality outcomes</span></p>
<p style="top:207.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">(Fig.</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff"> 2</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">). No difference was noted in the risk of mortality</span></p>
<p style="top:219.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">between CBT and control groups [Peto OR 0.94; 95% CI</span></p>
<p style="top:231.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">(0.05, 17.41),</span><span style="font-family:PrrxjsAdvTT8861b38f.I,serif;font-size:9.8pt;color:#131313"> p</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> = 0.94].</span></p>
<p style="top:256.0pt;left:56.7pt;line-height:9.2pt"><span style="font-family:HqrmbcAdvTT99c4c969,serif;font-size:9.2pt;color:#131313">CBT preserves cardiac function in animals</span></p>
<p style="top:268.0pt;left:56.7pt;line-height:9.2pt"><span style="font-family:QrkhyfAdvTT83913201.I,serif;font-size:9.2pt;color:#131313">Ejection fraction (EF)</span></p>
<p style="top:279.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Ten (56%) studies assessed either RVEF or LVEF. Ani-</span></p>
<p style="top:291.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">mals treated with CBT had an increased EF compared to</span></p>
<p style="top:303.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">control [MD 6.9%; 95% CI (4.24, 9.55);</span><span style="font-family:PrrxjsAdvTT8861b38f.I,serif;font-size:9.8pt;color:#131313"> p</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> &lt; 0.01], refer to</span></p>
<p style="top:315.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Fig.</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff"> 3</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> and Supplemental</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff"> 6</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">A-C.</span></p>
<p style="top:327.5pt;left:64.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">In subgroup analysis, intramyocardial delivery of cells</span></p>
<p style="top:339.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">at a dose of 1</span><span style="font-family:DljwryAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">10 M cells/kg, administered between</span></p>
<p style="top:351.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">1 week and 1 month after disease induction had the lar-</span></p>
<p style="top:363.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">gest impact on EF (</span><span style="font-family:PrrxjsAdvTT8861b38f.I,serif;font-size:9.8pt;color:#131313">p</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> &lt; 0.01). Furthermore, cardiac-</span></p>
<p style="top:375.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">derived cells from a non-autologous source optimized</span></p>
<p style="top:87.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">EF in animals (</span><span style="font-family:PrrxjsAdvTT8861b38f.I,serif;font-size:9.8pt;color:#131313">p</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> &lt; 0.01). Specifics can be seen in Supple-</span></p>
<p style="top:99.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">mental</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff"> 7</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">A-E. Bone marrow-derived mesenchymal stem</span></p>
<p style="top:111.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">cells (MSCs) demonstrated similar effects on EF to car-</span></p>
<p style="top:123.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">diac stem cells; however, there was only one study utiliz-</span></p>
<p style="top:135.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">ing bone marrow MSCs.</span></p>
<p style="top:160.0pt;left:304.7pt;line-height:9.2pt"><span style="font-family:QrkhyfAdvTT83913201.I,serif;font-size:9.2pt;color:#131313">Fractional shortening (FS)</span></p>
<p style="top:171.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Of the four studies assessing FS (</span><span style="font-family:PrrxjsAdvTT8861b38f.I,serif;font-size:9.8pt;color:#131313">n</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> = 83 animals), CBT</span></p>
<p style="top:183.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">demonstrated an improvement compared to controls</span></p>
<p style="top:195.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">[MD 4.09%; 95% CI (1.28, 6.91);</span><span style="font-family:PrrxjsAdvTT8861b38f.I,serif;font-size:9.8pt;color:#131313"> p</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> = 0.004 (Fig.</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff"> 4</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">)]. Sub-</span></p>
<p style="top:207.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">group analyses for FS paralleled the findings in EF for</span></p>
<p style="top:219.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">route; however, differed with regard to source, dose, and</span></p>
<p style="top:231.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">timing (Supplemental</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff"> 8</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">A-E).</span></p>
<p style="top:256.0pt;left:304.7pt;line-height:9.2pt"><span style="font-family:QrkhyfAdvTT83913201.I,serif;font-size:9.2pt;color:#131313">Other cardiac outcomes</span></p>
<p style="top:267.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">CBT treated trended towards preserving FAC (</span><span style="font-family:PrrxjsAdvTT8861b38f.I,serif;font-size:9.8pt;color:#131313">p</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> = 0.05)</span></p>
<p style="top:279.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">(Supplemental</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff"> 9</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">A). No difference was appreciated with</span></p>
<p style="top:291.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">respect to EDV, ESV, and TAPSE between the groups</span></p>
<p style="top:303.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">(Supplemental</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff"> 9</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">B-D).</span></p>
<p style="top:328.0pt;left:304.7pt;line-height:9.2pt"><span style="font-family:HqrmbcAdvTT99c4c969,serif;font-size:9.2pt;color:#131313">Clinical outcomes</span></p>
<p style="top:340.0pt;left:304.7pt;line-height:9.2pt"><span style="font-family:QrkhyfAdvTT83913201.I,serif;font-size:9.2pt;color:#131313">Study characteristics</span></p>
<p style="top:351.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Thirteen of the included studies were human (</span><span style="font-family:PrrxjsAdvTT8861b38f.I,serif;font-size:9.8pt;color:#131313">n</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> = 215).</span></p>
<p style="top:363.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">HLHS or single-ventricle physiology was the most repre-</span></p>
<p style="top:375.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">sented disease (</span><span style="font-family:PrrxjsAdvTT8861b38f.I,serif;font-size:9.8pt;color:#131313">n</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> = 183), with dilated cardiomyopathy</span></p>
<p style="top:708.7pt;left:62.7pt;line-height:8.0pt"><span style="font-family:QlgxmbAdvTTaf7f9f4f.B,serif;font-size:8.0pt;color:#131313">Fig. 3</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> Effect size of regenerative cells on animal ejection fraction. Forest plot demonstrating MD and 95% CI. Cell based,</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:8.0pt;color:#131313"> n</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> = 256; Control,</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:8.0pt;color:#131313"> n</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> = 261;</span></p>
<p style="top:718.7pt;left:62.7pt;line-height:8.0pt"><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:8.0pt;color:#131313">p</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> &lt; 0.00001. Rightward of the line of null effect favors cell based group, leftward favors control</span></p>
<p style="top:32.6pt;left:56.7pt;line-height:8.0pt"><span style="font-family:TqgscwAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Martinez</span><span style="font-family:XdxhkwAdvTT7329fd89.I,serif;font-size:8.0pt;color:#131313"> et al. Stem Cell Research &amp; Therapy</span><span style="font-family:MyriadPro,serif;font-size:8.0pt;color:#131313">          (2020) 11:272 </span></p>
<p style="top:32.6pt;left:496.1pt;line-height:8.0pt"><span style="font-family:TqgscwAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Page 6 of 13</span></p>


<p style="top:315.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">making up the remainder (</span><span style="font-family:PrrxjsAdvTT8861b38f.I,serif;font-size:9.8pt;color:#131313">n</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> = 32). All studies reported</span></p>
<p style="top:327.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">safety and greater than 90% commented on efficacy of</span></p>
<p style="top:339.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">CBT (</span><span style="font-family:PrrxjsAdvTT8861b38f.I,serif;font-size:9.8pt;color:#131313">n</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> = 206). Study details are described in Table</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff"> 2</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">.</span></p>
<p style="top:375.0pt;left:56.7pt;line-height:9.2pt"><span style="font-family:QrkhyfAdvTT83913201.I,serif;font-size:9.2pt;color:#131313">Intervention characteristics</span></p>
<p style="top:386.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">All human studies isolated autologous cells. Cardiac tis-</span></p>
<p style="top:398.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">sue (</span><span style="font-family:PrrxjsAdvTT8861b38f.I,serif;font-size:9.8pt;color:#131313">n</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> = 170, 79%) with intracoronary infusion (</span><span style="font-family:PrrxjsAdvTT8861b38f.I,serif;font-size:9.8pt;color:#131313">n</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> = 204,</span></p>
<p style="top:410.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">95%) was the most common tissue source and form of</span></p>
<p style="top:422.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">delivery, respectively. The studies administered CBT in-</span></p>
<p style="top:434.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">traoperatively or greater than 1 month after isolation of</span></p>
<p style="top:446.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">cells at a dose of 3.0 &#xd7; 10</span><sup><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:6.9pt;color:#131313">5</span></sup><sup><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> </span></sup><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">cells/kg to 5.4 &#xd7; 10</span><sup><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:6.9pt;color:#131313">7</span></sup><sup><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> </span></sup><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">cells/kg.</span></p>
<p style="top:458.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">A summary of study characteristics is provided in Sup-</span></p>
<p style="top:470.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">plemental Table</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff"> 4</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">.</span></p>
<p style="top:506.0pt;left:56.7pt;line-height:9.2pt"><span style="font-family:HqrmbcAdvTT99c4c969,serif;font-size:9.2pt;color:#131313">Cell-based/derived therapies are safe in humans</span></p>
<p style="top:518.0pt;left:56.7pt;line-height:9.2pt"><span style="font-family:QrkhyfAdvTT83913201.I,serif;font-size:9.2pt;color:#131313">Adverse events</span></p>
<p style="top:529.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Patients treated with CBT had less adverse events com-</span></p>
<p style="top:541.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">pared to controls [44/492 vs. 98/606, Peto OR 0.17; 95%</span></p>
<p style="top:553.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">CI (0.09, 0.30);</span><span style="font-family:PrrxjsAdvTT8861b38f.I,serif;font-size:9.8pt;color:#131313"> p</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> &lt; 0.01]. Cardiac and respiratory events</span></p>
<p style="top:565.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">were most frequently reported and both favored CBT</span></p>
<p style="top:577.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">[Peto OR 0.11; 95% CI (0.05, 0.23);</span><span style="font-family:PrrxjsAdvTT8861b38f.I,serif;font-size:9.8pt;color:#131313"> p</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> &lt; 0.01] and [Peto</span></p>
<p style="top:589.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">OR 0.16; 95% CI (0.03, 0.95);</span><span style="font-family:PrrxjsAdvTT8861b38f.I,serif;font-size:9.8pt;color:#131313"> p</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> &lt; 0.05], respectively. No</span></p>
<p style="top:601.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">difference was observed in GI, hematologic, infectious,</span></p>
<p style="top:613.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">or systemic events. The frequency of occurrence of over-</span></p>
<p style="top:625.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">all and system-specific adverse events is outlined in Sup-</span></p>
<p style="top:637.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">plemental Table</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff"> 5</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">. Adverse event specifics are detailed</span></p>
<p style="top:649.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">in Supplemental Table</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff"> 2</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">.</span></p>
<p style="top:685.0pt;left:56.7pt;line-height:9.2pt"><span style="font-family:QrkhyfAdvTT83913201.I,serif;font-size:9.2pt;color:#131313">Mortality</span></p>
<p style="top:696.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">One human study reported events of mortality, which</span></p>
<p style="top:708.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">demonstrated a 7.3% death rate for CBT versus 15% for</span></p>
<p style="top:720.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">the control group (</span><span style="font-family:PrrxjsAdvTT8861b38f.I,serif;font-size:9.8pt;color:#131313">p</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> &gt; 0.05) [</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">30</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">].</span></p>
<p style="top:316.0pt;left:304.7pt;line-height:9.2pt"><span style="font-family:HqrmbcAdvTT99c4c969,serif;font-size:9.2pt;color:#131313">CBT preserves cardiac function in humans</span></p>
<p style="top:328.0pt;left:304.7pt;line-height:9.2pt"><span style="font-family:QrkhyfAdvTT83913201.I,serif;font-size:9.2pt;color:#131313">Ejection fraction (EF)</span></p>
<p style="top:339.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">CBT preserved EF compared to controls [MD 4.84; 95%</span></p>
<p style="top:351.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">CI (1.62, 8.07);</span><span style="font-family:PrrxjsAdvTT8861b38f.I,serif;font-size:9.8pt;color:#131313"> p</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> &lt; 0.05], refer to Fig.</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff"> 5</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">. While twelve of</span></p>
<p style="top:363.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">thirteen studies assessed EF, only three of those studies</span></p>
<p style="top:375.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">underwent meta-analysis due to lack of a suitable con-</span></p>
<p style="top:387.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">trol arm in the remaining [</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">24</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">,</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff"> 31</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">,</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff"> 33</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">]. One study did not</span></p>
<p style="top:399.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">report efficacy [</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">29</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">]. Given the paucity of studies asses-</span></p>
<p style="top:411.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">sing EF, subgroup analysis in the human studies was not</span></p>
<p style="top:423.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">performed.</span></p>
<p style="top:459.0pt;left:304.7pt;line-height:9.2pt"><span style="font-family:QrkhyfAdvTT83913201.I,serif;font-size:9.2pt;color:#131313">Narrative findings of EF</span></p>
<p style="top:470.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Nine studies underwent qualitative analysis due to lack</span></p>
<p style="top:482.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">of comparison groups or absence of specified efficacy</span></p>
<p style="top:494.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">outcomes [</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">21</span><span style="font-family:DljwryAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">23</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">,</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff"> 25</span><span style="font-family:DljwryAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">28</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">,</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff"> 30</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">,</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff"> 32</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">]. Overall, the majority</span></p>
<p style="top:506.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">of CBT-treated patients demonstrated a trend towards</span></p>
<p style="top:518.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">increased EF compared to baseline. Most notably, Sano</span></p>
<p style="top:530.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">et al. observed an 8.4% improvement in EF vs. 1.6% in</span></p>
<p style="top:542.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">control following stage II palliation and a 7.9% improve-</span></p>
<p style="top:554.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">ment vs.</span><span style="font-family:YpcsjpAdvTT86d47313+22,serif;font-size:9.8pt;color:#131313"> &#x2212;</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> 1.1% at stage III palliation. Of note, Sano was</span></p>
<p style="top:566.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">excluded from meta-analysis given outcomes reported in</span></p>
<p style="top:578.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">terms of delta EF rather than absolute change. Rupp and</span></p>
<p style="top:590.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Rivas reported an improvement in EF by 22% from base-</span></p>
<p style="top:602.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">line at the 3 and 4-month follow-up, respectively [</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">27</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">,</span></p>
<p style="top:614.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">28</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">]. Pincott et al. noted no difference in EF compared to</span></p>
<p style="top:626.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">baseline [</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">25</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">]. Burkhart et al. and Eitoku both observed</span></p>
<p style="top:638.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">improvement in RVEF in their respective studies [</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">21</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">,</span></p>
<p style="top:650.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">23</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">].</span></p>
<p style="top:662.5pt;left:312.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Notably, Zschirnt reports a substantial improvement</span></p>
<p style="top:674.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">in LVEF of 24% from baseline [</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">32</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">]. Results from Burkart</span></p>
<p style="top:686.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">et al. 2019 indicate that intramyocardial injection of um-</span></p>
<p style="top:698.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">bilical cord blood-derived cells at the time of stage II</span></p>
<p style="top:710.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">palliation preserves baseline RVEF [</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">22</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">]. Lastly, Qureshi</span></p>
<p style="top:722.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">et al showed an increase in EF from 34 to 38% by</span></p>
<p style="top:272.2pt;left:62.7pt;line-height:8.0pt"><span style="font-family:QlgxmbAdvTTaf7f9f4f.B,serif;font-size:8.0pt;color:#131313">Fig. 4</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> Effect size of regenerative cells on animal fractional shortening. Forest plot demonstrating MD and 95% CI. Cell based,</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:8.0pt;color:#131313"> n</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> = 175; Control,</span></p>
<p style="top:282.2pt;left:62.7pt;line-height:8.0pt"><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:8.0pt;color:#131313">n</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> = 171;</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:8.0pt;color:#131313"> p</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> = 0.004. Rightward of the line of null effect favors cell based group, leftward favors control</span></p>
<p style="top:32.6pt;left:56.7pt;line-height:8.0pt"><span style="font-family:TqgscwAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Martinez</span><span style="font-family:XdxhkwAdvTT7329fd89.I,serif;font-size:8.0pt;color:#131313"> et al. Stem Cell Research &amp; Therapy</span><span style="font-family:MyriadPro,serif;font-size:8.0pt;color:#131313">          (2020) 11:272 </span></p>
<p style="top:32.6pt;left:496.1pt;line-height:8.0pt"><span style="font-family:TqgscwAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Page 7 of 13</span></p>


<p style="top:447.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">cardiac magnetic resonance imaging at the 6-month</span></p>
<p style="top:459.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">follow-up in their case report [</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">26</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">].</span></p>
<p style="top:484.0pt;left:56.7pt;line-height:9.2pt"><span style="font-family:QrkhyfAdvTT83913201.I,serif;font-size:9.2pt;color:#131313">Other cardiac outcomes</span></p>
<p style="top:495.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Zero human studies assessed the effects of CBT on FS.</span></p>
<p style="top:507.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">FAC and EDV were analyzed in three studies (Supple-</span></p>
<p style="top:519.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">mental</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff"> 10</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">A and</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff"> 10</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">B, respectively). Three studies pro-</span></p>
<p style="top:531.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">vided data for ESV analysis (Supplemental</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff"> 10C</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">). Three</span></p>
<p style="top:543.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">studies mentioned TAPSE, but none could undergo ana-</span></p>
<p style="top:555.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">lysis due to the absence of a comparison arm. In sum,</span></p>
<p style="top:567.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">no significant differences were observed in FAC, EDV,</span></p>
<p style="top:579.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">or ESV when comparing CBT to control (Supplementals</span></p>
<p style="top:591.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">10</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">A</span><span style="font-family:DljwryAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">C).</span></p>
<p style="top:616.0pt;left:56.7pt;line-height:9.2pt"><span style="font-family:HqrmbcAdvTT99c4c969,serif;font-size:9.2pt;color:#131313">Risk of bias</span></p>
<p style="top:627.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">No animal study fulfilled all ten criteria for low risk of</span></p>
<p style="top:639.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">bias (Supplemental</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff"> 11</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">). One study [</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">12</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">] met eight of the</span></p>
<p style="top:651.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">criteria for a low risk of bias and four [</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">10</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">,</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff"> 11</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">,</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff"> 14</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">,</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff"> 34</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">]</span></p>
<p style="top:663.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">studies met seven of the criteria. All studies were</span></p>
<p style="top:675.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">deemed to be at low risk of bias for similar groups at</span></p>
<p style="top:687.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">baseline, complete data, and selective reporting. One</span></p>
<p style="top:699.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">study was at high risk for other biases [</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">13</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">]. Visually ap-</span></p>
<p style="top:711.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">parent asymmetry was present in the funnel plot of frac-</span></p>
<p style="top:723.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">tional shortening while minimal asymmetry was present</span></p>
<p style="top:447.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">in the funnel plot of ejection fraction, thus denoting a</span></p>
<p style="top:459.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">lack of publication bias (Supplemental Figs.</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff"> 13</span><span style="font-family:DljwryAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">14</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">).</span></p>
<p style="top:471.5pt;left:312.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">The ROBINS-I risk of bias assessment tool was</span></p>
<p style="top:483.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">employed for human studies (Supplemental</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff"> 12</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">,</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff"> 13</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">, and</span></p>
<p style="top:495.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">14</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">). One study fulfilled all five criteria for low risk of</span></p>
<p style="top:507.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">bias [</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">25</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">]. All studies performed their intended interven-</span></p>
<p style="top:519.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">tions without deviations and reported complete data</span></p>
<p style="top:531.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">with a low risk of bias [</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">21</span><span style="font-family:DljwryAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">33</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">]. Ten studies described</span></p>
<p style="top:543.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">randomization procedures with a high risk of bias [</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">21</span><span style="font-family:DljwryAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span></p>
<p style="top:555.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">23</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">,</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff"> 26</span><span style="font-family:DljwryAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">32</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">], while only one study demonstrated concerns</span></p>
<p style="top:567.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">of bias for selective reporting [</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">28</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">].</span></p>
<p style="top:591.1pt;left:304.7pt;line-height:10.3pt"><span style="font-family:QlgxmbAdvTTaf7f9f4f.B,serif;font-size:10.3pt;color:#131313">Discussion</span></p>
<p style="top:603.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Our review performed a meta-analysis of cell-based ther-</span></p>
<p style="top:615.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">apies used in the treatment of animal models of pediatric</span></p>
<p style="top:627.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">heart disease and in pediatric patients with congenital</span></p>
<p style="top:639.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">and acquired cardiac dysfunction.</span></p>
<p style="top:651.5pt;left:312.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Our outcomes of interest included safety and efficacy.</span></p>
<p style="top:663.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Safety was stratified into mortality and the occurrence of</span></p>
<p style="top:675.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">adverse events, which were assessed by system-specific</span></p>
<p style="top:687.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">prevalence. Cell-based therapies proved to be safe in</span></p>
<p style="top:699.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">comparison to placebo in both animal and human stud-</span></p>
<p style="top:711.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">ies. Efficacy was defined by various measures of cardiac</span></p>
<p style="top:723.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">function. Of those, cell therapies preserved ejection</span></p>
<p style="top:87.9pt;left:56.7pt;line-height:9.0pt"><span style="font-family:QlgxmbAdvTTaf7f9f4f.B,serif;font-size:9.0pt;color:#131313">Table 2</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:9.0pt;color:#131313"> Overview of clinical study details</span></p>
<p style="top:101.6pt;left:56.7pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Author</span></p>
<p style="top:109.7pt;left:56.7pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">(year)</span></p>
<p style="top:101.6pt;left:97.7pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Study</span></p>
<p style="top:109.7pt;left:97.7pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">design</span></p>
<p style="top:101.6pt;left:125.9pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Human</span></p>
<p style="top:109.7pt;left:125.9pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">characteristics</span></p>
<p style="top:101.6pt;left:190.1pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Intervention characteristics</span></p>
<p style="top:101.6pt;left:364.4pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Outcome measures</span></p>
<p style="top:121.8pt;left:97.7pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Study</span></p>
<p style="top:129.8pt;left:97.7pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">type</span></p>
<p style="top:121.8pt;left:125.9pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Disease</span></p>
<p style="top:121.8pt;left:152.8pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Age</span></p>
<p style="top:121.8pt;left:190.1pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Cell type; source</span></p>
<p style="top:129.8pt;left:190.1pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">(origin)</span></p>
<p style="top:121.8pt;left:254.5pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Total dose (cells/kg); route; timing of</span></p>
<p style="top:129.8pt;left:254.5pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">delivery; frequency</span></p>
<p style="top:121.8pt;left:364.4pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Timing of assessment</span></p>
<p style="top:121.8pt;left:469.0pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Ventricular function</span></p>
<p style="top:129.8pt;left:469.0pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">mode of assessment</span></p>
<p style="top:141.9pt;left:56.7pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Burkhart</span></p>
<p style="top:149.9pt;left:56.7pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">et al. [</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt;color:#0000ff">21</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:141.9pt;left:97.7pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Case</span></p>
<p style="top:149.9pt;left:97.7pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">report</span></p>
<p style="top:141.9pt;left:125.9pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">HLHS</span></p>
<p style="top:141.9pt;left:152.8pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">4 months</span></p>
<p style="top:141.9pt;left:190.1pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Umbilical cord</span></p>
<p style="top:149.9pt;left:190.1pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">blood (autologous)</span></p>
<p style="top:141.9pt;left:254.5pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">3.0 &#xd7; 10</span><sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:4.9pt">6</span></sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">; intramyocardial; at time of</span></p>
<p style="top:149.9pt;left:254.5pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">stage II palliation; once</span></p>
<p style="top:141.9pt;left:364.4pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Baseline and 3 months</span></p>
<p style="top:141.9pt;left:469.0pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Echo</span></p>
<p style="top:162.9pt;left:56.7pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Burkhart</span></p>
<p style="top:170.9pt;left:56.7pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">et al. [</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt;color:#0000ff">22</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:162.9pt;left:97.7pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Phase I</span></p>
<p style="top:162.9pt;left:125.9pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">HLHS</span></p>
<p style="top:162.9pt;left:152.8pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">3</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">6</span></p>
<p style="top:170.9pt;left:152.8pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">months</span></p>
<p style="top:162.9pt;left:190.1pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Umbilical cord</span></p>
<p style="top:170.9pt;left:190.1pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">blood (autologous)</span></p>
<p style="top:162.9pt;left:254.5pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">3.0 &#xd7; 10</span><sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:4.9pt">6</span></sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">; intramyocardial; during</span></p>
<p style="top:170.9pt;left:254.5pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">stage II palliation; once</span></p>
<p style="top:162.9pt;left:364.4pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Baseline, discharge, 1 month,</span></p>
<p style="top:170.9pt;left:364.4pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">3 months, and 6 months</span></p>
<p style="top:162.9pt;left:469.0pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Echo</span></p>
<p style="top:183.9pt;left:56.7pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Eitoku et al.</span></p>
<p style="top:191.9pt;left:56.7pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt;color:#0000ff">23</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:183.9pt;left:97.7pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Phase</span></p>
<p style="top:191.9pt;left:97.7pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">I/II</span></p>
<p style="top:183.9pt;left:125.9pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">SV</span></p>
<p style="top:183.9pt;left:152.8pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">5</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">70</span></p>
<p style="top:191.9pt;left:152.8pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">months</span></p>
<p style="top:183.9pt;left:190.1pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Cardiac (autologous)</span></p>
<p style="top:183.9pt;left:254.5pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">3.0 &#xd7; 10</span><sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:4.9pt">5</span></sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">; intracoronary; 1-month</span></p>
<p style="top:191.9pt;left:254.5pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">post-staged palliation; once</span></p>
<p style="top:183.9pt;left:364.4pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Baseline, 3 years</span></p>
<p style="top:183.9pt;left:469.0pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Cardiac MRI</span></p>
<p style="top:205.0pt;left:56.7pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Ishigami</span></p>
<p style="top:213.0pt;left:56.7pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">et al. (2014)</span></p>
<p style="top:205.0pt;left:97.7pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Phase I</span></p>
<p style="top:205.0pt;left:125.9pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">HLHS</span></p>
<p style="top:205.0pt;left:152.8pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">1.5 years</span></p>
<p style="top:205.0pt;left:190.1pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Cardiac (autologous)</span></p>
<p style="top:205.0pt;left:254.5pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">3.0 &#xd7; 10</span><sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:4.9pt">5</span></sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">; intracoronary; 1-month</span></p>
<p style="top:213.0pt;left:254.5pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">post-staged palliation; once</span></p>
<p style="top:205.0pt;left:364.4pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Baseline, 3 months, 6 months,</span></p>
<p style="top:213.0pt;left:364.4pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">12 months, and 18 months</span></p>
<p style="top:205.0pt;left:469.0pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Echo, cardiac MRI</span></p>
<p style="top:225.9pt;left:56.7pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Ishigami</span></p>
<p style="top:233.9pt;left:56.7pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">et al. [</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt;color:#0000ff">24</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:225.9pt;left:97.7pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Phase II</span></p>
<p style="top:225.9pt;left:125.9pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">SV</span></p>
<p style="top:225.9pt;left:152.8pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">1.2</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">4.2</span></p>
<p style="top:233.9pt;left:152.8pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">years</span></p>
<p style="top:225.9pt;left:190.1pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Cardiac (autologous)</span></p>
<p style="top:225.9pt;left:254.5pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">3.0 &#xd7; 10</span><sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:4.9pt">5</span></sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">; intracoronary; 1-month</span></p>
<p style="top:233.9pt;left:254.5pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">post-staged palliation; once</span></p>
<p style="top:225.9pt;left:364.4pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Baseline, 3 months</span></p>
<p style="top:225.9pt;left:469.0pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Cardiac MRI</span></p>
<p style="top:246.9pt;left:56.7pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Pincott</span></p>
<p style="top:254.9pt;left:56.7pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">et al. [</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt;color:#0000ff">25</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:246.9pt;left:97.7pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Phase</span></p>
<p style="top:254.9pt;left:97.7pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">I/II</span></p>
<p style="top:246.9pt;left:125.9pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">DCM</span></p>
<p style="top:246.9pt;left:152.8pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">1</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">16 years</span></p>
<p style="top:246.9pt;left:190.1pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Bone marrow</span></p>
<p style="top:254.9pt;left:190.1pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">(autologous)</span></p>
<p style="top:246.9pt;left:254.5pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">5.4 &#xd7; 10</span><sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:4.9pt">7b</span></sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">; intracoronary; within 1 h</span></p>
<p style="top:254.9pt;left:254.5pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">of harvest; once</span></p>
<p style="top:246.9pt;left:364.4pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Baseline, 6 moths</span></p>
<p style="top:246.9pt;left:469.0pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Cardiac MRI, Cath</span></p>
<p style="top:267.9pt;left:56.7pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Qureshi</span></p>
<p style="top:275.9pt;left:56.7pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">et al. [</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt;color:#0000ff">26</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:267.9pt;left:97.7pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Case</span></p>
<p style="top:275.9pt;left:97.7pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">report</span></p>
<p style="top:267.9pt;left:125.9pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">HLHS</span></p>
<p style="top:267.9pt;left:152.8pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">25 years</span></p>
<p style="top:267.9pt;left:190.1pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Bone marrow</span></p>
<p style="top:275.9pt;left:190.1pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">(autologous)</span></p>
<p style="top:267.9pt;left:254.5pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">2.0 &#xd7; 10</span><sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:4.9pt">6</span></sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">; intracoronary; within 3 h</span></p>
<p style="top:275.9pt;left:254.5pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">of harvest; once</span></p>
<p style="top:267.9pt;left:364.4pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Baseline, 1 month, 3 months,</span></p>
<p style="top:275.9pt;left:364.4pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">6 months</span></p>
<p style="top:267.9pt;left:469.0pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Echo</span></p>
<p style="top:288.9pt;left:56.7pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Rivas et al.</span></p>
<p style="top:296.9pt;left:56.7pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt;color:#0000ff">27</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:288.9pt;left:97.7pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Case</span></p>
<p style="top:296.9pt;left:97.7pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">report</span></p>
<p style="top:288.9pt;left:125.9pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">DCM</span></p>
<p style="top:288.9pt;left:152.8pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">3</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">4</span></p>
<p style="top:296.9pt;left:152.8pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">months</span></p>
<p style="top:288.9pt;left:190.1pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Bone marrow</span></p>
<p style="top:296.9pt;left:190.1pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">(autologous)</span></p>
<p style="top:288.9pt;left:254.5pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">8.35 &#xd7; 10</span><sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:4.9pt">6a</span></sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">; intracoronary; 2 h post-</span></p>
<p style="top:296.9pt;left:254.5pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">isolation; once</span></p>
<p style="top:288.9pt;left:364.4pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Baseline, 1 week, 4 weeks,</span></p>
<p style="top:296.9pt;left:364.4pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">8 weeks, and 17 weeks</span></p>
<p style="top:288.9pt;left:469.0pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Echo</span></p>
<p style="top:310.0pt;left:56.7pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Rupp et al.</span></p>
<p style="top:317.9pt;left:56.7pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt;color:#0000ff">28</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:310.0pt;left:97.7pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Case</span></p>
<p style="top:317.9pt;left:97.7pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">report</span></p>
<p style="top:310.0pt;left:125.9pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">HLHS</span></p>
<p style="top:310.0pt;left:152.8pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">11 months</span></p>
<p style="top:310.0pt;left:190.1pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Bone marrow</span></p>
<p style="top:317.9pt;left:190.1pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">(autologous)</span></p>
<p style="top:310.0pt;left:254.5pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">DNR; intracoronary; day of harvest;</span></p>
<p style="top:317.9pt;left:254.5pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">once</span></p>
<p style="top:310.0pt;left:364.4pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Baseline, 3 months</span></p>
<p style="top:310.0pt;left:469.0pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Echo, cardiac MRI</span></p>
<p style="top:330.9pt;left:56.7pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Rupp et al.</span></p>
<p style="top:338.9pt;left:56.7pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt;color:#0000ff">29</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:330.9pt;left:97.7pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Phase</span></p>
<p style="top:338.9pt;left:97.7pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">I/II</span></p>
<p style="top:330.9pt;left:125.9pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">DCM</span></p>
<p style="top:330.9pt;left:152.8pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">4 months-</span></p>
<p style="top:338.9pt;left:152.8pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">16 years</span></p>
<p style="top:330.9pt;left:190.1pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Bone marrow</span></p>
<p style="top:338.9pt;left:190.1pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">(autologous)</span></p>
<p style="top:330.9pt;left:254.5pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">DNR; intracoronary; day of harvest;</span></p>
<p style="top:338.9pt;left:254.5pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">once</span></p>
<p style="top:330.9pt;left:364.4pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Baseline, 2</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">3 months, 24</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.0pt">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">52</span></p>
<p style="top:338.9pt;left:364.4pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">months</span></p>
<p style="top:330.9pt;left:469.0pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">DNR</span></p>
<p style="top:351.9pt;left:56.7pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Sano et al.</span></p>
<p style="top:360.0pt;left:56.7pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt;color:#0000ff">30</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:351.9pt;left:97.7pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Phase I</span></p>
<p style="top:351.9pt;left:125.9pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">SV</span></p>
<p style="top:351.9pt;left:152.8pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">8 months-</span></p>
<p style="top:360.0pt;left:152.8pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">3.1 years</span></p>
<p style="top:351.9pt;left:190.1pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Cardiac (autologous)</span></p>
<p style="top:351.9pt;left:254.5pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">3.0 &#xd7; 10</span><sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:4.9pt">5</span></sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">; intracoronary;</span></p>
<p style="top:360.0pt;left:254.5pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">intraoperative (stage II or III); once</span></p>
<p style="top:351.9pt;left:364.4pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Baseline, 1 year, 2 years post-</span></p>
<p style="top:360.0pt;left:364.4pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">palliation</span></p>
<p style="top:351.9pt;left:469.0pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Echo</span></p>
<p style="top:372.9pt;left:56.7pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Tarui et al.</span></p>
<p style="top:380.9pt;left:56.7pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">[</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt;color:#0000ff">31</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:372.9pt;left:97.7pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Phase I</span></p>
<p style="top:372.9pt;left:125.9pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">HLHS</span></p>
<p style="top:372.9pt;left:152.8pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">1.5 years</span></p>
<p style="top:372.9pt;left:190.1pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Cardiac (autologous)</span></p>
<p style="top:372.9pt;left:254.5pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">3.0 &#xd7; 10</span><sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:4.9pt">5</span></sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">; intracoronary; 1-month</span></p>
<p style="top:380.9pt;left:254.5pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">post-staged palliation; once</span></p>
<p style="top:372.9pt;left:364.4pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Baseline, 36 months</span></p>
<p style="top:372.9pt;left:469.0pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Cardiac MRI</span></p>
<p style="top:393.9pt;left:56.7pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Zschirnt</span></p>
<p style="top:401.9pt;left:56.7pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">et al. [</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt;color:#0000ff">32</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">]</span></p>
<p style="top:393.9pt;left:97.7pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Case</span></p>
<p style="top:401.9pt;left:97.7pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">report</span></p>
<p style="top:393.9pt;left:125.9pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">DCM</span></p>
<p style="top:393.9pt;left:152.8pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">DNR</span></p>
<p style="top:393.9pt;left:190.1pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Bone marrow</span></p>
<p style="top:401.9pt;left:190.1pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">(autologous)</span></p>
<p style="top:393.9pt;left:254.5pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">2.4 &#xd7; 10</span><sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:4.9pt">7</span></sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">; intracoronary; DNR; once</span></p>
<p style="top:393.9pt;left:364.4pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Baseline, 4 months</span></p>
<p style="top:393.9pt;left:469.0pt;line-height:7.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.0pt">Cardiac MRI</span></p>
<p style="top:414.6pt;left:56.7pt;line-height:7.0pt"><span style="font-family:XdxhkwAdvTT7329fd89.I,serif;font-size:7.0pt">HLHS</span><span style="font-family:TqgscwAdvTTe45e47d2,serif;font-size:7.0pt"> hypoplastic left heart syndrome,</span><span style="font-family:XdxhkwAdvTT7329fd89.I,serif;font-size:7.0pt"> SV</span><span style="font-family:TqgscwAdvTTe45e47d2,serif;font-size:7.0pt"> single ventricle,</span><span style="font-family:XdxhkwAdvTT7329fd89.I,serif;font-size:7.0pt"> DCM</span><span style="font-family:TqgscwAdvTTe45e47d2,serif;font-size:7.0pt"> dilated cardiomyopathy,</span><span style="font-family:XdxhkwAdvTT7329fd89.I,serif;font-size:7.0pt"> DNR</span><span style="font-family:TqgscwAdvTTe45e47d2,serif;font-size:7.0pt"> did not report</span></p>
<p style="top:421.1pt;left:56.7pt;line-height:4.9pt"><span style="font-family:TqgscwAdvTTe45e47d2,serif;font-size:4.9pt">a</span><span style="font-family:TqgscwAdvTTe45e47d2,serif;font-size:7.0pt">Absolute cell count</span></p>
<p style="top:429.1pt;left:56.7pt;line-height:4.9pt"><span style="font-family:TqgscwAdvTTe45e47d2,serif;font-size:4.9pt">b</span><span style="font-family:TqgscwAdvTTe45e47d2,serif;font-size:7.0pt">Dose obtained based on additional study cited within paper</span></p>
<p style="top:32.6pt;left:56.7pt;line-height:8.0pt"><span style="font-family:TqgscwAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Martinez</span><span style="font-family:XdxhkwAdvTT7329fd89.I,serif;font-size:8.0pt;color:#131313"> et al. Stem Cell Research &amp; Therapy</span><span style="font-family:MyriadPro,serif;font-size:8.0pt;color:#131313">          (2020) 11:272 </span></p>
<p style="top:32.6pt;left:496.1pt;line-height:8.0pt"><span style="font-family:TqgscwAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Page 8 of 13</span></p>


<p style="top:447.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">fraction in animals and humans. To further understand</span></p>
<p style="top:459.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">variables that may modulate effect size on ejection frac-</span></p>
<p style="top:471.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">tion, subgroup analysis was performed in pre-clinical</span></p>
<p style="top:483.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">studies based on delivery route, timing of administration,</span></p>
<p style="top:495.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">tissue source, and dose.</span></p>
<p style="top:507.5pt;left:64.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">To date, pediatric clinical trials are evaluating the</span></p>
<p style="top:519.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">safety of cell-based interventions for hypoplastic left</span></p>
<p style="top:531.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">heart syndrome. Standard of care for this condition en-</span></p>
<p style="top:543.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">tails a three-staged surgical approach over the first</span></p>
<p style="top:555.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">2 years of life. However, a subset of individuals develops</span></p>
<p style="top:567.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">right ventricular failure, as this chamber is not anatom-</span></p>
<p style="top:579.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">ically or physiologically adept to maintain systemic cir-</span></p>
<p style="top:591.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">culation. The current goal of cell-based therapies is to</span></p>
<p style="top:603.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">bridge the patient during surgical inter-stages by main-</span></p>
<p style="top:615.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">taining right ventricular function. Therefore, the use of</span></p>
<p style="top:627.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">cell therapies in pediatric heart disease is being investi-</span></p>
<p style="top:639.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">gated as an adjunct to surgery versus surgery alone.</span></p>
<p style="top:651.5pt;left:64.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Timing of delivery appeared to have the greatest effect</span></p>
<p style="top:663.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">size on ejection fraction in pre-clinical studies. Cell ther-</span></p>
<p style="top:675.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">apies administered 1 week to 1 month after disease</span></p>
<p style="top:687.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">model induction preserved EF by 10.6%. The impact of</span></p>
<p style="top:699.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">timing of cellular delivery on efficacy is well recognized.</span></p>
<p style="top:711.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Hu et al. described a time-dependent therapeutic effect</span></p>
<p style="top:723.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">in a rat model of myocardial infarction (MI). Rats</span></p>
<p style="top:447.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">receiving intramyocardial injection 1 week after induc-</span></p>
<p style="top:459.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">tion of disease model demonstrated the greatest preser-</span></p>
<p style="top:471.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">vation in EF compared to those receiving cell therapies</span></p>
<p style="top:483.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">at initial induction or at a later time point [</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">35</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">]. Crisos-</span></p>
<p style="top:495.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">tomo et al. observed comparable results in a larger swine</span></p>
<p style="top:507.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">model of MI. Swine receiving intracoronary cardiac por-</span></p>
<p style="top:519.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">cine cells at 2 h post induction of disease model demon-</span></p>
<p style="top:531.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">strated greater decline in EF in comparison to those that</span></p>
<p style="top:543.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">received cells 7 days post induction [</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">36</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">]. These results</span></p>
<p style="top:555.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">have translated to human studies. A meta-analysis per-</span></p>
<p style="top:567.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">formed by Xu et al. of 34 randomized control trials</span></p>
<p style="top:579.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">(RCT) revealed that administration of the autologous</span></p>
<p style="top:591.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">bone marrow cells 3</span><span style="font-family:DljwryAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">7 days post percutaneous coronary</span></p>
<p style="top:603.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">intervention optimized efficacy [</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">37</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">]. Timing of delivery</span></p>
<p style="top:615.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">appears to play a role in the efficacy of cell-based therap-</span></p>
<p style="top:627.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">ies. Immediate administration at onset of disease model</span></p>
<p style="top:639.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">appears sub-optimal. Nitkin et al. described a critical</span><span style="font-family:DljwryAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313"> &#x201c;</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">in-</span></p>
<p style="top:651.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">flection</span><span style="font-family:DljwryAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x201d;</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> point in the disease course where therapeutic</span></p>
<p style="top:663.4pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">effects are maximal [</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">38</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">]. Future clinical studies of cellu-</span></p>
<p style="top:675.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">lar therapies for pediatric heart disease should prioritize</span></p>
<p style="top:687.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">elucidating the optimal timing of cellular administration.</span></p>
<p style="top:699.4pt;left:312.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">The studies included herein transplant the stem cells</span></p>
<p style="top:711.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">in a variety of administrative routes, including intracor-</span></p>
<p style="top:723.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">onary, intramyocardial, intravenous, graft/patch/sheet,</span></p>
<p style="top:402.0pt;left:62.7pt;line-height:8.0pt"><span style="font-family:QlgxmbAdvTTaf7f9f4f.B,serif;font-size:8.0pt;color:#131313">Fig. 5</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> Effect size of regenerative cells on human ejection fraction. Forest plot demonstrating MD and 95% CI. Cell based,</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:8.0pt;color:#131313"> n</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> = 221; Control,</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:8.0pt;color:#131313"> n</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> =</span></p>
<p style="top:411.9pt;left:62.7pt;line-height:8.0pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313">221;</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:8.0pt;color:#131313"> p</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:8.0pt;color:#131313"> = 0.003. Rightward of the line of null effect favors cell based group, leftward favors control</span></p>
<p style="top:32.6pt;left:56.7pt;line-height:8.0pt"><span style="font-family:TqgscwAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Martinez</span><span style="font-family:XdxhkwAdvTT7329fd89.I,serif;font-size:8.0pt;color:#131313"> et al. Stem Cell Research &amp; Therapy</span><span style="font-family:MyriadPro,serif;font-size:8.0pt;color:#131313">          (2020) 11:272 </span></p>
<p style="top:32.6pt;left:496.1pt;line-height:8.0pt"><span style="font-family:TqgscwAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Page 9 of 13</span></p>


<p style="top:87.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">and epicardial. Intramyocardial delivery of stem cells</span></p>
<p style="top:99.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">demonstrated the most favorable effect on EF in pre-</span></p>
<p style="top:111.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">clinical studies with a MD of 7.35%. Although intraven-</span></p>
<p style="top:123.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">ous delivery of CBT yielded a comparable effect on EF</span></p>
<p style="top:135.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">in animal studies (9.3%), only one study evaluated this</span></p>
<p style="top:147.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">route, and therefore, results should be taken guardedly.</span></p>
<p style="top:159.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">A meta-analysis published by Kanelidis et al. demon-</span></p>
<p style="top:171.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">strated how the route of delivery modulates the efficacy</span></p>
<p style="top:183.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">of mesenchymal stem cell therapy for MI in pre-clinical</span></p>
<p style="top:195.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">and clinical studies. While transendocardial stem cell in-</span></p>
<p style="top:207.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">jection yielded the greatest improvement in infarct size</span></p>
<p style="top:219.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">and EF for both pre-clinical and clinical studies, the</span></p>
<p style="top:231.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">study also illustrated beneficial effects of intramyocardial</span></p>
<p style="top:243.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">delivery on EF in pre-clinical studies. Of note, intramyo-</span></p>
<p style="top:255.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">cardial delivery of stem cells has not been studied in tri-</span></p>
<p style="top:267.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">als focusing on acute MI as this route requires open-</span></p>
<p style="top:279.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">heart surgery and deviates from the current standard of</span></p>
<p style="top:291.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">treatment which entails cardiac cathetherization [</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">7</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">].</span></p>
<p style="top:303.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Brunskill et al. also investigated the route of delivery and</span></p>
<p style="top:315.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">found that the intramyocardial delivery of stem cells op-</span></p>
<p style="top:327.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">timizes the effects of trials investigating acute MI and is-</span></p>
<p style="top:339.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">chemic heart disease [</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">39</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">]. Altogether, these findings</span></p>
<p style="top:351.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">suggest that the route of cell therapy delivery may affect</span></p>
<p style="top:363.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">cardiac efficacy.</span></p>
<p style="top:375.5pt;left:64.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Cell therapies of cardiac origin demonstrated a 9.2%</span></p>
<p style="top:387.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">preservation of EF in animal models. Cardiac stem cells</span></p>
<p style="top:399.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">have historically been an attractive therapeutic option</span></p>
<p style="top:411.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">due to their high angiogenic potential, balanced para-</span></p>
<p style="top:423.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">crine profile, and ability to differentiate into myocardial</span></p>
<p style="top:435.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">lineages when compared to other cell types [</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">40</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">,</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff"> 41</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">]. A</span></p>
<p style="top:447.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">meta-analysis performed by Zwetsloot et al. including</span></p>
<p style="top:459.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">1970 animals receiving cardiac cells demonstrated an</span></p>
<p style="top:471.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">improved ejection fraction by 10.7%. When stratifying by</span></p>
<p style="top:483.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">type of cardiac cell (cardiosphere derived, cardiosphere,</span></p>
<p style="top:495.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">c-kit+, sca-1+), variable improvements of 12.9%, 11.8%,</span></p>
<p style="top:507.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">10.7, and 8.3% were observed [</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">41</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">]. Translating these</span></p>
<p style="top:519.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">findings into human clinical trials remains challenging.</span></p>
<p style="top:531.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">For instance, a recently published phase I/II double-</span></p>
<p style="top:543.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">blinded RCT in patients with ST-segment elevation MI</span></p>
<p style="top:555.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">revealed no significant difference between patients re-</span></p>
<p style="top:567.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">ceiving cardiac stem cells and placebo [</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">42</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">]. Moreover,</span></p>
<p style="top:579.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">there exists considerable heterogeneity in tissue source</span></p>
<p style="top:591.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">being utilized in pediatric clinical trials. In this review,</span></p>
<p style="top:603.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">bone marrow-derived MSCs demonstrated similar ef-</span></p>
<p style="top:615.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">fects on EF to cardiac stem cells (9.3%), yet these results</span></p>
<p style="top:627.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">should be interpreted with caution as only one study in-</span></p>
<p style="top:639.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">cluded the use of bone marrow MSCs. Of the included</span></p>
<p style="top:651.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">pediatric clinical studies in this review, 38% are utilizing</span></p>
<p style="top:663.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">CBT of cardiac origin whereas the remainder provided</span></p>
<p style="top:675.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">umbilical cord blood and bone marrow MSCs. Future</span></p>
<p style="top:687.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">trials should examine the tissue source most likely to</span></p>
<p style="top:699.4pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">provide cardiac benefit.</span></p>
<p style="top:711.5pt;left:64.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">This review revealed that a dose of 1</span><span style="font-family:DljwryAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">10 M cells/kg</span></p>
<p style="top:723.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">modulated EF by 8.4%. It is unsurprising that the efficacy</span></p>
<p style="top:87.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">of cell therapies appears to be dose-dependent. This ob-</span></p>
<p style="top:99.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">servation has been reported in both pre-clinical studies</span></p>
<p style="top:111.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">and human clinical trials of acute myocardial infarction.</span></p>
<p style="top:123.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Tang et al. describes a rat model of MI where five differ-</span></p>
<p style="top:135.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">ent escalating doses of cardiac stem cells were tested</span></p>
<p style="top:147.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">(0.3 &#xd7; 10</span><sup><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:6.9pt;color:#131313">6</span></sup><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">, 0.75 &#xd7; 10</span><sup><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:6.9pt;color:#131313">6</span></sup><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">,1.5 &#xd7; 10</span><sup><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:6.9pt;color:#131313">6</span></sup><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">, 3.0 &#xd7; 10</span><sup><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:6.9pt;color:#131313">6</span></sup><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">, 6.0 &#xd7; 10</span><sup><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:6.9pt;color:#131313">6</span></sup><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">). The</span></p>
<p style="top:159.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">lowest dose had no effect on LV function; doses ranging</span></p>
<p style="top:171.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">0.75</span><span style="font-family:DljwryAdvTT86d47313+20,serif;font-size:9.8pt;color:#131313">&#x2013;</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">3.0 &#xd7; 10</span><sup><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:6.9pt;color:#131313">6</span></sup><sup><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> </span></sup><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">provided a similar cardiac benefit. Inter-</span></p>
<p style="top:183.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">estingly, post procedure mortality increased with 6.0 &#xd7;</span></p>
<p style="top:195.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">10</span><sup><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:6.9pt;color:#131313">6</span></sup><sup><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> </span></sup><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">cells. These results suggest an optimal dose required</span></p>
<p style="top:207.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">for efficacy in addition to a dosage plateau where no</span></p>
<p style="top:219.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">additional benefits are observed [</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">43</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">]. Spoel and col-</span></p>
<p style="top:231.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">leagues note similar findings in a meta-analysis of 52</span></p>
<p style="top:243.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">large animal models utilizing cardiac stem cells for treat-</span></p>
<p style="top:255.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">ment of acute MI. Transplantation of doses greater than</span></p>
<p style="top:267.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">10</span><sup><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:6.9pt;color:#131313">7</span></sup><sup><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> </span></sup><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">cells had the greatest impact on improvement in</span></p>
<p style="top:279.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">LVEF [</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">44</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">]. Xu and co-authors performed a meta-</span></p>
<p style="top:291.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">analysis including 40 RCT, assessing 1927 patients, re-</span></p>
<p style="top:303.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">ceiving bone marrow-derived cells in the treatment of</span></p>
<p style="top:315.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">acute myocardial infarction. There appears to be a dose-</span></p>
<p style="top:327.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">dependent effect in efficacy. No differences were ob-</span></p>
<p style="top:339.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">served in patients receiving</span><span style="font-family:YpcsjpAdvTT86d47313+22,serif;font-size:9.8pt;color:#131313"> &#x2264;</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> 10</span><sup><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:6.9pt;color:#131313">7</span></sup><sup><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> </span></sup><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">cells or 10</span><sup><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:6.9pt;color:#131313">9</span></sup><sup><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313"> </span></sup><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">cells [</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">37</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">].</span></p>
<p style="top:351.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">These findings provide evidence that an optimal dose</span></p>
<p style="top:363.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">will also be observed in pediatric patients. Of the 13 hu-</span></p>
<p style="top:375.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">man studies included in this review, 30% are utilizing</span></p>
<p style="top:387.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">doses between 1 and 10 M cells/kg with high variability</span></p>
<p style="top:399.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">in dosage between remaining studies.</span></p>
<p style="top:411.5pt;left:312.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">As noted previously, studies on cell therapies in animal</span></p>
<p style="top:423.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">models with MI have shown favorable effects on cardiac</span></p>
<p style="top:435.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">function. While these studies prompted investigation for</span></p>
<p style="top:447.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">the use of stem cells in pediatric heart disease, one must</span></p>
<p style="top:459.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">be cautious when comparing degrees of efficacy from</span></p>
<p style="top:471.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">adult to pediatric studies. The pathophysiology of heart</span></p>
<p style="top:483.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">failure in the setting of myocardial infarction differs</span></p>
<p style="top:495.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">from that which causes heart failure in children. More-</span></p>
<p style="top:507.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">over, heart failure in pediatric heart disease is largely at-</span></p>
<p style="top:519.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">tributed to right ventricular dysfunction as opposed to</span></p>
<p style="top:531.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">left ventricular dysfunction in adults. Ischemic heart fail-</span></p>
<p style="top:543.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">ure is most frequently due to LV systolic dysfunction</span></p>
<p style="top:555.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">with the leading cause due to loss of functional myocar-</span></p>
<p style="top:567.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">dium secondary to ischemic disease [</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">45</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">], whereas heart</span></p>
<p style="top:579.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">failure in children can be attributed to several mecha-</span></p>
<p style="top:591.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">nisms including alterations to pressure or volume load,</span></p>
<p style="top:603.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">valvular abnormalities, electromechanical dysynchrony,</span></p>
<p style="top:615.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">coronary anomalies, and myocardial fibrosis [</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">46</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">]. While</span></p>
<p style="top:627.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">previous studies on cell therapies in adults can provide</span></p>
<p style="top:639.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">significant insight, it is unsuitable to make a direct com-</span></p>
<p style="top:651.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">parison of cell-based therapies and their potential effects</span></p>
<p style="top:663.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">in two varied populations.</span></p>
<p style="top:675.5pt;left:312.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">This review evaluated the safety of administration of</span></p>
<p style="top:687.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">cell-based therapies in pre-clinical models of pediatric</span></p>
<p style="top:699.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">heart disease and in children with congenital or acquired</span></p>
<p style="top:711.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">heart disease. Cell-based therapies are generally regarded</span></p>
<p style="top:723.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">as safe for administration. In this review, no significant</span></p>
<p style="top:32.6pt;left:56.7pt;line-height:8.0pt"><span style="font-family:TqgscwAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Martinez</span><span style="font-family:XdxhkwAdvTT7329fd89.I,serif;font-size:8.0pt;color:#131313"> et al. Stem Cell Research &amp; Therapy</span><span style="font-family:MyriadPro,serif;font-size:8.0pt;color:#131313">          (2020) 11:272 </span></p>
<p style="top:32.6pt;left:492.0pt;line-height:8.0pt"><span style="font-family:TqgscwAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Page 10 of 13</span></p>


<p style="top:87.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">differences were observed in animal mortality or occur-</span></p>
<p style="top:99.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">rence of adverse events. Only one of thirteen human</span></p>
<p style="top:111.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">studies explicitly commented on mortality. An important</span></p>
<p style="top:123.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">finding in human studies was that less cardiac and re-</span></p>
<p style="top:135.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">spiratory events were observed in the cell-based group.</span></p>
<p style="top:147.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Demonstrating safety after CBT was paralleled in a</span></p>
<p style="top:159.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">meta-analysis done by Thompson et al. of MSCs deliv-</span></p>
<p style="top:171.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">ered across a multitude of diseases. Compared to con-</span></p>
<p style="top:183.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">trols, there was no increased risk of death, infusion</span></p>
<p style="top:195.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">toxicity, infection, thrombotic/embolic events, or malig-</span></p>
<p style="top:207.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">nancy. However, there was an acutely increased risk of</span></p>
<p style="top:219.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">fever associated with administration of cell products</span></p>
<p style="top:231.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">compared to control [</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">47</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">]. In another review, Lalu et al.</span></p>
<p style="top:243.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">report no significant differences in the occurrence of ad-</span></p>
<p style="top:255.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">verse events in the cell group vs control group [</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">4</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">].</span></p>
<p style="top:280.0pt;left:56.7pt;line-height:9.2pt"><span style="font-family:HqrmbcAdvTT99c4c969,serif;font-size:9.2pt;color:#131313">Limitations</span></p>
<p style="top:291.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Although the results of our meta-analysis and subsequent</span></p>
<p style="top:303.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">subgroup analysis are promising, they should be interpreted</span></p>
<p style="top:315.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">with caution. It is conceivable that the observed optimal</span></p>
<p style="top:327.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">route of delivery, dose, timing, and tissue source may not</span></p>
<p style="top:339.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">truly reflect ideal therapeutic parameters. Moreover, they</span></p>
<p style="top:351.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">may be a mere reflection of the parameters most often used</span></p>
<p style="top:363.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">by investigators in the field. Future studies will need to indi-</span></p>
<p style="top:375.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">vidually investigate and optimize each variable to achieve</span></p>
<p style="top:387.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">maximal therapeutic benefits. An additional limitation of</span></p>
<p style="top:399.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">this study arises from the early stage of human clinical trials</span></p>
<p style="top:411.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">for congenital and acquired pediatric heart disease. The</span></p>
<p style="top:423.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">simple lack of data created a challenge in completion of a</span></p>
<p style="top:435.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">robust meta-analysis for human studies. As more trials are</span></p>
<p style="top:447.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">completed, a future meta-analysis needs to be performed to</span></p>
<p style="top:459.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">assess the reproducibility of our reported results. Currently,</span></p>
<p style="top:471.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">there are six ongoing clinical trials (Supplemental Table</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff"> 6</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">).</span></p>
<p style="top:483.5pt;left:64.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">A large degree of heterogeneity was detected in both</span></p>
<p style="top:495.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">the pre-clinical and clinical studies included in this re-</span></p>
<p style="top:507.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">view. Recently, the Transnational Alliance for Regenera-</span></p>
<p style="top:519.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">tive Therapies in Cardiovascular Syndromes (TACTICS)</span></p>
<p style="top:531.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">identified areas of focus in cell-based therapies for car-</span></p>
<p style="top:543.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">diovascular disease. Moreover, the methodologic rigor of</span></p>
<p style="top:555.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">translational research was pinpointed as a main area of</span></p>
<p style="top:567.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">concern, wherein the experts proposed the following</span></p>
<p style="top:579.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">themes as ways to improve translational success: internal</span></p>
<p style="top:591.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">validity, standardization of protocols (cell source, dose,</span></p>
<p style="top:603.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">timing, etc.), and multicenter animal studies [</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#0000ff">48</span><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">]. This</span></p>
<p style="top:615.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">lack of standardization has led to a high degree of vari-</span></p>
<p style="top:627.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">ability in the efficacy of regenerative therapies for</span></p>
<p style="top:639.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">pediatric heart disease. In doing so, perhaps we will</span></p>
<p style="top:651.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">begin to see more consistently reproducible positive hu-</span></p>
<p style="top:663.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">man results.</span></p>
<p style="top:687.1pt;left:56.7pt;line-height:10.3pt"><span style="font-family:QlgxmbAdvTTaf7f9f4f.B,serif;font-size:10.3pt;color:#131313">Conclusion</span></p>
<p style="top:699.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">Cell-based therapies are safe in both animal models of</span></p>
<p style="top:711.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">pediatric heart disease and in human clinical trials of</span></p>
<p style="top:723.5pt;left:56.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">congenital and acquired cardiac disease. These cells</span></p>
<p style="top:87.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">appear to serve a role in the preservation of specific</span></p>
<p style="top:99.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">measures of cardiac function. Their efficacy appears</span></p>
<p style="top:111.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">modulated by the route and timing of delivery, dose, and</span></p>
<p style="top:123.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">tissue source. Implications from this review may provide</span></p>
<p style="top:135.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">methodologic recommendations for current and future</span></p>
<p style="top:147.5pt;left:304.7pt;line-height:9.8pt"><span style="font-family:QyxyhnAdvTT86d47313,serif;font-size:9.8pt;color:#131313">clinical studies.</span></p>
<p style="top:177.9pt;left:304.7pt;line-height:10.3pt"><span style="font-family:QlgxmbAdvTTaf7f9f4f.B,serif;font-size:10.3pt;color:#131313">Supplementary information</span></p>
<p style="top:189.1pt;left:304.7pt;line-height:7.5pt"><span style="font-family:HqrmbcAdvTT99c4c969,serif;font-size:7.5pt;color:#131313">Supplementary information</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313"> accompanies this paper at</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#0000ff"> https://doi.org/10.</span></p>
<p style="top:198.2pt;left:304.7pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#0000ff">1186/s13287-020-01764-x</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">.</span></p>
<p style="top:220.4pt;left:310.0pt;line-height:7.5pt"><span style="font-family:QlgxmbAdvTTaf7f9f4f.B,serif;font-size:7.5pt;color:#131313">Additional file 1 Supplemental 1.</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313"> PROSPERO registration</span></p>
<p style="top:229.4pt;left:310.0pt;line-height:7.5pt"><span style="font-family:QlgxmbAdvTTaf7f9f4f.B,serif;font-size:7.5pt;color:#131313">Supplemental 2.</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313"> SYRCLE criteria for animal intervention studies.</span></p>
<p style="top:238.5pt;left:310.0pt;line-height:7.5pt"><span style="font-family:QlgxmbAdvTTaf7f9f4f.B,serif;font-size:7.5pt;color:#131313">Supplemental 3.</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313"> Database search terms.</span><span style="font-family:QlgxmbAdvTTaf7f9f4f.B,serif;font-size:7.5pt;color:#131313"> Supplemental 4.</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313"> List of</span></p>
<p style="top:247.5pt;left:310.0pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">included studies.</span><span style="font-family:QlgxmbAdvTTaf7f9f4f.B,serif;font-size:7.5pt;color:#131313"> Supplemental 5.</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313"> PRISMA Checklist.</span><span style="font-family:QlgxmbAdvTTaf7f9f4f.B,serif;font-size:7.5pt;color:#131313"> Supplemental 6.</span></p>
<p style="top:256.4pt;left:310.0pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">Effect size of regenerative cell on animal ejection fraction. Forest plots</span></p>
<p style="top:265.4pt;left:310.0pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">demonstrating MD and 95% CI for A) Left ventricular ejection fraction;</span></p>
<p style="top:274.5pt;left:310.0pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">cell-based</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:7.5pt;color:#131313"> n</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">=172; control=177;</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:7.5pt;color:#131313"> p</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313"> &lt;0.0001. B) Right ventricular ejection</span></p>
<p style="top:283.5pt;left:310.0pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">fraction; cell-based</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:7.5pt;color:#131313"> n</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">=84; control n=84;</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:7.5pt;color:#131313"> p</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">=0.02. C) Disease model; cell-</span></p>
<p style="top:292.4pt;left:310.0pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">based</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:7.5pt;color:#131313"> n</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">= 256; control</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:7.5pt;color:#131313"> n</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">=261; RVHF,</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:7.5pt;color:#131313"> p</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">=0.01; DCM,</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:7.5pt;color:#131313"> p</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">&lt;0.0001.</span><span style="font-family:QlgxmbAdvTTaf7f9f4f.B,serif;font-size:7.5pt;color:#131313"> Supplemen-</span></p>
<p style="top:301.4pt;left:310.0pt;line-height:7.5pt"><span style="font-family:QlgxmbAdvTTaf7f9f4f.B,serif;font-size:7.5pt;color:#131313">tal 7.</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313"> Subgroup analysis of regenerative cell effect size on animal ejec-</span></p>
<p style="top:310.5pt;left:310.0pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">tion fraction. Forest plots demonstrating MD and 95% CI for A) Route of</span></p>
<p style="top:319.5pt;left:310.0pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">delivery,</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:7.5pt;color:#131313"> p</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">&lt;0.00001 for intramyocardial injection. B) Dose,</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:7.5pt;color:#131313"> p</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">&lt;0.00001 for</span></p>
<p style="top:328.4pt;left:310.0pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">1-10 M. C) Tissue Source,</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:7.5pt;color:#131313"> p</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">&lt;0.0001 for cardiac;</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:7.5pt;color:#131313"> p</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">=0.0003 for bone mar-</span></p>
<p style="top:337.4pt;left:310.0pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">row. D) Timing of delivery,</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:7.5pt;color:#131313"> p</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">&lt;0.0001 for 1 week</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.5pt;color:#131313">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">1 month. E) autologous</span></p>
<p style="top:346.5pt;left:310.0pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">vs. non-autologous sources,</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:7.5pt;color:#131313"> p</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">&lt;0.0001 (non-autologous). Cell-based n=</span></p>
<p style="top:355.5pt;left:310.0pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">256; Control n=261.</span><span style="font-family:QlgxmbAdvTTaf7f9f4f.B,serif;font-size:7.5pt;color:#131313"> Supplemental 8.</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313"> Subgroup analysis of regenerative</span></p>
<p style="top:364.4pt;left:310.0pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">cell effect size on animal fractional shortening. Forest plots demonstrating</span></p>
<p style="top:373.4pt;left:310.0pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">MD and 95% CI for A) Route of delivery,</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:7.5pt;color:#131313"> p</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">=0.001 for intramyocardial. B)</span></p>
<p style="top:382.5pt;left:310.0pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">Dose,</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:7.5pt;color:#131313"> p</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">=0.001 for &gt;10 M cells/kg. C) Tissue Source,</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:7.5pt;color:#131313"> p</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">=0 .001 for umbilical</span></p>
<p style="top:391.5pt;left:310.0pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">cord blood. D) Timing of delivery,</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:7.5pt;color:#131313"> p</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">=0.001 for &gt;1 month. E) Disease</span></p>
<p style="top:400.4pt;left:310.0pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">model,</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:7.5pt;color:#131313"> p</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">=0.001 for dilated cardiomyopathy. Cell-based</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:7.5pt;color:#131313"> n</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">=175; Control</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:7.5pt;color:#131313"> n</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">=</span></p>
<p style="top:409.4pt;left:310.0pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">171.</span><span style="font-family:QlgxmbAdvTTaf7f9f4f.B,serif;font-size:7.5pt;color:#131313"> Supplemental 9.</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313"> Effect size of regenerative cell on additional mea-</span></p>
<p style="top:418.5pt;left:310.0pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">sures of animal cardiac function. Forest plots demonstrating MD and 95%</span></p>
<p style="top:427.5pt;left:310.0pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">CI for A) Fractional area change,</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:7.5pt;color:#131313"> p</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">=0.05; cell-based</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:7.5pt;color:#131313"> n</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">= 33; control</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:7.5pt;color:#131313"> n</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">=30.</span></p>
<p style="top:436.4pt;left:310.0pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">B) End diastolic volume,</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:7.5pt;color:#131313"> p</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">=0.48; cell-based</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:7.5pt;color:#131313"> n</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">=67; control</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:7.5pt;color:#131313"> n</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">=61. C) End</span></p>
<p style="top:445.4pt;left:310.0pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">systolic volume,</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:7.5pt;color:#131313"> p</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">=0.60; cell-based</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:7.5pt;color:#131313"> n</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">=72; control</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:7.5pt;color:#131313"> n</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">=66. D) Tricuspid annu-</span></p>
<p style="top:454.5pt;left:310.0pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">lar plane systolic excursion,</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:7.5pt;color:#131313"> p</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">=0.55; cell-based</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:7.5pt;color:#131313"> n</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">=33; control</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:7.5pt;color:#131313"> n</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">=58.</span><span style="font-family:QlgxmbAdvTTaf7f9f4f.B,serif;font-size:7.5pt;color:#131313"> Sup-</span></p>
<p style="top:463.5pt;left:310.0pt;line-height:7.5pt"><span style="font-family:QlgxmbAdvTTaf7f9f4f.B,serif;font-size:7.5pt;color:#131313">plemental 10.</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313"> Effect size of regenerative cell on additional measures of</span></p>
<p style="top:472.4pt;left:310.0pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">human cardiac function. Forest plots demonstrating MD and 95% CI for</span></p>
<p style="top:481.4pt;left:310.0pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">A) Fractional area change,</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:7.5pt;color:#131313"> p</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">-0.19; cell-based</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:7.5pt;color:#131313"> n</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">=62; control</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:7.5pt;color:#131313"> n</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">=62. B) End</span></p>
<p style="top:490.5pt;left:310.0pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">diastolic volume,</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:7.5pt;color:#131313"> p</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">=0.52; cell-based</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:7.5pt;color:#131313"> n</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">=110; control</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:7.5pt;color:#131313"> n</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">=110. C) End systolic</span></p>
<p style="top:499.5pt;left:310.0pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">volume,</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:7.5pt;color:#131313"> p</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">=0.96; cell-based</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:7.5pt;color:#131313"> n</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">=110; control</span><span style="font-family:VgdjtcAdvTT1b53b5fb.I,serif;font-size:7.5pt;color:#131313"> n</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">=110.</span><span style="font-family:QlgxmbAdvTTaf7f9f4f.B,serif;font-size:7.5pt;color:#131313"> Supplemental 11.</span></p>
<p style="top:508.4pt;left:310.0pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">SYRCLE risk of bias for animal studies.</span><span style="font-family:QlgxmbAdvTTaf7f9f4f.B,serif;font-size:7.5pt;color:#131313"> Supplemental 12.</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313"> ROBINS-I risk of</span></p>
<p style="top:517.4pt;left:310.0pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">bias for human studies.</span><span style="font-family:QlgxmbAdvTTaf7f9f4f.B,serif;font-size:7.5pt;color:#131313"> Supplemental 13.</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313"> Funnel plot diagram for ani-</span></p>
<p style="top:526.5pt;left:310.0pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">mal ejection fraction.</span><span style="font-family:QlgxmbAdvTTaf7f9f4f.B,serif;font-size:7.5pt;color:#131313"> Supplemental 14.</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313"> Funnel plot diagram for animal</span></p>
<p style="top:535.5pt;left:310.0pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">fractional shortening.</span><span style="font-family:QlgxmbAdvTTaf7f9f4f.B,serif;font-size:7.5pt;color:#131313"> Supplemental Table 1.</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313"> Animal study intervention</span></p>
<p style="top:544.4pt;left:310.0pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">characteristics.</span><span style="font-family:QlgxmbAdvTTaf7f9f4f.B,serif;font-size:7.5pt;color:#131313"> Supplemental Table 2.</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313"> Adverse events by systems.</span><span style="font-family:QlgxmbAdvTTaf7f9f4f.B,serif;font-size:7.5pt;color:#131313"> Sup-</span></p>
<p style="top:553.4pt;left:310.0pt;line-height:7.5pt"><span style="font-family:QlgxmbAdvTTaf7f9f4f.B,serif;font-size:7.5pt;color:#131313">plemental Table 3.</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313"> Animal adverse events.</span><span style="font-family:QlgxmbAdvTTaf7f9f4f.B,serif;font-size:7.5pt;color:#131313"> Supplemental Table 4.</span></p>
<p style="top:562.5pt;left:310.0pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">Human study intervention characteristics.</span><span style="font-family:QlgxmbAdvTTaf7f9f4f.B,serif;font-size:7.5pt;color:#131313"> Supplemental Table 5.</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313"> Hu-</span></p>
<p style="top:571.5pt;left:310.0pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">man adverse events.</span><span style="font-family:QlgxmbAdvTTaf7f9f4f.B,serif;font-size:7.5pt;color:#131313"> Supplemental Table 6.</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313"> Clinical trials, ongoing.</span></p>
<p style="top:601.5pt;left:304.7pt;line-height:7.5pt"><span style="font-family:HqrmbcAdvTT99c4c969,serif;font-size:7.5pt;color:#131313">Abbreviations</span></p>
<p style="top:610.5pt;left:304.7pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt">CBT:</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313"> Cell-based/derived therapies; CCHD: Critical congenital heart disease;</span></p>
<p style="top:619.5pt;left:304.7pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">CI: Confidence interval; EDV: End diastolic volume; ESV: End systolic volume;</span></p>
<p style="top:628.5pt;left:304.7pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">EF: Ejection fraction; FAC: Fractional area change; FS: Fractional shortening;</span></p>
<p style="top:637.5pt;left:304.7pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">HLHS: Hypoplastic left heart syndrome; LVEF: Left ventricular ejection</span></p>
<p style="top:646.5pt;left:304.7pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">fraction; MD: Mean difference; MRI: Magnetic resonance imaging; OR: Odds</span></p>
<p style="top:655.5pt;left:304.7pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">ratio; PROSPERO: International database of systematic reviews and meta-</span></p>
<p style="top:664.5pt;left:304.7pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">analysis; ROBINS: Risk of bias in non-randomized studies of interventions;</span></p>
<p style="top:673.5pt;left:304.7pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">RV: Right ventricle; RVEF: Right ventricular ejection fraction;</span></p>
<p style="top:682.5pt;left:304.7pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">SYRCLE: Systematic Review Centre for Laboratory Animal Experimentation;</span></p>
<p style="top:691.5pt;left:304.7pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">TAPSE: Tricuspid annular plane systolic excursion</span></p>
<p style="top:716.3pt;left:304.7pt;line-height:7.5pt"><span style="font-family:HqrmbcAdvTT99c4c969,serif;font-size:7.5pt;color:#131313">Acknowledgements</span></p>
<p style="top:725.3pt;left:304.7pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">None.</span></p>
<p style="top:32.6pt;left:56.7pt;line-height:8.0pt"><span style="font-family:TqgscwAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Martinez</span><span style="font-family:XdxhkwAdvTT7329fd89.I,serif;font-size:8.0pt;color:#131313"> et al. Stem Cell Research &amp; Therapy</span><span style="font-family:MyriadPro,serif;font-size:8.0pt;color:#131313">          (2020) 11:272 </span></p>
<p style="top:32.6pt;left:492.0pt;line-height:8.0pt"><span style="font-family:TqgscwAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Page 11 of 13</span></p>


<p style="top:89.4pt;left:56.7pt;line-height:7.5pt"><span style="font-family:HqrmbcAdvTT99c4c969,serif;font-size:7.5pt;color:#131313">Authors</span><span style="font-family:BdmgxxAdvTT99c4c969+20,serif;font-size:7.5pt;color:#131313">&#x2019;</span><span style="font-family:HqrmbcAdvTT99c4c969,serif;font-size:7.5pt;color:#131313"> contributions</span></p>
<p style="top:98.3pt;left:56.7pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">JM participated in the study design and carried out data collection, risk of</span></p>
<p style="top:107.3pt;left:56.7pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">bias, initial statistics, and manuscript writing. SZ carried out data collection</span></p>
<p style="top:116.3pt;left:56.7pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">and assembled tables, risk of bias, and manuscript writing. AxM participated</span></p>
<p style="top:125.4pt;left:56.7pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">in the study design and carried out the manuscript writing. AM participated</span></p>
<p style="top:134.3pt;left:56.7pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">in the study design, advised on data to be collected, risk of bias, supervised</span></p>
<p style="top:143.3pt;left:56.7pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">all activities, all statistical computations, and final manuscript drafting. The</span></p>
<p style="top:152.3pt;left:56.7pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">authors read and approved the final manuscript.</span></p>
<p style="top:172.8pt;left:56.7pt;line-height:7.5pt"><span style="font-family:HqrmbcAdvTT99c4c969,serif;font-size:7.5pt;color:#131313">Funding</span></p>
<p style="top:181.8pt;left:56.7pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">This work was supported by the Parker B. Francis Fellowship Grant [to A.M.]</span></p>
<p style="top:190.8pt;left:56.7pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">and the National Institutes of Health National Center for Advancing</span></p>
<p style="top:199.9pt;left:56.7pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">Translational Sciences [KL2 TR001118 to A.M.].</span></p>
<p style="top:220.3pt;left:56.7pt;line-height:7.5pt"><span style="font-family:HqrmbcAdvTT99c4c969,serif;font-size:7.5pt;color:#131313">Availability of data and materials</span></p>
<p style="top:229.3pt;left:56.7pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">The data underlying this article are available in the article and in its online</span></p>
<p style="top:238.3pt;left:56.7pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">supplementary material.</span></p>
<p style="top:258.8pt;left:56.7pt;line-height:7.5pt"><span style="font-family:HqrmbcAdvTT99c4c969,serif;font-size:7.5pt;color:#131313">Ethics approval and consent to participate</span></p>
<p style="top:267.8pt;left:56.7pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">Not applicable, review article of published data</span></p>
<p style="top:288.3pt;left:56.7pt;line-height:7.5pt"><span style="font-family:HqrmbcAdvTT99c4c969,serif;font-size:7.5pt;color:#131313">Consent for publication</span></p>
<p style="top:297.3pt;left:56.7pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">Not applicable, review article of published data</span></p>
<p style="top:317.8pt;left:56.7pt;line-height:7.5pt"><span style="font-family:HqrmbcAdvTT99c4c969,serif;font-size:7.5pt;color:#131313">Competing interests</span></p>
<p style="top:326.8pt;left:56.7pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">The authors declare that they have no competing interests.</span></p>
<p style="top:344.8pt;left:56.7pt;line-height:7.5pt"><span style="font-family:HqrmbcAdvTT99c4c969,serif;font-size:7.5pt;color:#131313">Author details</span></p>
<p style="top:352.2pt;left:56.7pt;line-height:5.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:5.3pt">1</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt">Department of Pediatrics, University of Texas Health San Antonio, San</span></p>
<p style="top:362.8pt;left:56.7pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt">Antonio, TX 77229, USA.</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:5.3pt"> </span><sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:5.3pt">2</span></sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt">Department of Pediatrics, Texas Children</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.5pt">&#x2019;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt">s Hospital,</span></p>
<p style="top:371.9pt;left:56.7pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt">Houston, TX 77030, USA.</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:5.3pt"> </span><sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:5.3pt">3</span></sup><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt">Department of Pediatrics, UT Health San Antonio,</span></p>
<p style="top:380.8pt;left:56.7pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt">7703 Floyd Curl Drive, MC 7812, San Antonio, TX 78229, USA.</span></p>
<p style="top:398.8pt;left:56.7pt;line-height:7.5pt"><span style="font-family:TqgscwAdvTTe45e47d2,serif;font-size:7.5pt;color:#131313">Received: 10 May 2020 Revised: 4 June 2020</span></p>
<p style="top:407.9pt;left:56.7pt;line-height:7.5pt"><span style="font-family:TqgscwAdvTTe45e47d2,serif;font-size:7.5pt;color:#131313">Accepted: 8 June 2020</span></p>
<img style="position:absolute;transform:matrix(.15999878,0,-0,.16000001,-287.76466,504.26008)" src="data:image/png;base64,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">
<p style="top:437.5pt;left:56.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">1.</span><sup><span style="font-family:HqrmbcAdvTT99c4c969,serif;font-size:7.5pt;color:#131313">References</span></sup></p>
<p style="top:437.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Stout KK, Broberg CS, Book WM, Cecchin F, Chen JM, Dimopoulos K, et al.</span></p>
<p style="top:446.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Chronic heart failure in congenital heart disease: a scientific statement from</span></p>
<p style="top:455.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">the American Heart Association. Circulation. 2016;133(8):770</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">801..</span></p>
<p style="top:464.5pt;left:56.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2.</span></p>
<p style="top:464.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Chamsi-Pasha M, Chamsi-Pasha H. Critical congenital heart disease</span></p>
<p style="top:473.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">screening. Avicenna J Med. 2016;6(3):65.</span></p>
<p style="top:482.5pt;left:56.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">3.</span></p>
<p style="top:482.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Oster ME, Lee KA, Honein MA, Riehle-Colarusso T, Correa A. Temporal trends</span></p>
<p style="top:491.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">in survival among infants with critical congenital heart defects HHS public</span></p>
<p style="top:500.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">access. Pediatrics. 2013;131(5):1502</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">8.</span></p>
<p style="top:509.5pt;left:56.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">4.</span></p>
<p style="top:509.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Lalu MM, Mazzarello S, Zlepnig J, Dong YY (Ryan), Montroy J, McIntyre L,</span></p>
<p style="top:518.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">et al. Safety and efficacy of adult stem cell therapy for acute myocardial</span></p>
<p style="top:527.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">infarction and ischemic heart failure (SafeCell Heart): a systematic review</span></p>
<p style="top:536.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">and meta-analysis. Stem Cells Transl Med 2018;7(12):857</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">866.</span></p>
<p style="top:545.5pt;left:56.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">5.</span></p>
<p style="top:545.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Fan M, Huang Y, Chen Z, Xia Y, Chen A, Lu D, et al. Efficacy of mesenchymal</span></p>
<p style="top:554.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">stem cell therapy in systolic heart failure: a systematic review and meta-</span></p>
<p style="top:563.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">analysis. Stem Cell Res Ther. 2019;10(1):1</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">14.</span></p>
<p style="top:572.5pt;left:56.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">6.</span></p>
<p style="top:572.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Rong S-L, Wang Z-K, Zhou X-D, Wang X-L, Yang Z-M, Li B. Efficacy and</span></p>
<p style="top:581.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">safety of stem cell therapy in patients with dilated cardiomyopathy: a</span></p>
<p style="top:590.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">systematic appraisal and meta-analysis. J Transl Med. 2019;17(1):1</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">14.</span></p>
<p style="top:599.5pt;left:56.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">7.</span></p>
<p style="top:599.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Kanelidis AJ, Premer C, Lopez J, Balkan W, Hare JM. Route of delivery</span></p>
<p style="top:608.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">modulates the efficacy of mesenchymal stem cell therapy for myocardial</span></p>
<p style="top:617.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">infarction: a meta-analysis of preclinical studies and clinical trials. Circ Res.</span></p>
<p style="top:626.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2017;120(7):1139</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">50.</span></p>
<p style="top:635.5pt;left:56.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">8.</span></p>
<p style="top:635.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Tsilimigras DI, Oikonomou EK, Moris D, Schizas D, Economopoulos KP,</span></p>
<p style="top:644.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Mylonas KS. Stem cell therapy for congenital heart disease: a systematic</span></p>
<p style="top:653.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">review. Circulation. 2017;24:2373</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">85 Lippincott Williams &amp;</span></p>
<p style="top:662.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">WilkinsHagerstown, MD.</span></p>
<p style="top:671.5pt;left:56.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">9.</span></p>
<p style="top:671.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Wehman B, Kaushal S. The emergence of stem cell therapy for patients with</span></p>
<p style="top:680.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">congenital heart disease. Circ Res. 2015;116(4):566</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">9.</span></p>
<p style="top:689.5pt;left:56.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">10.</span></p>
<p style="top:689.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Agarwal U, Smith AW, French KM, Boopathy AV, George A, Trac D, et al.</span></p>
<p style="top:698.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Age-dependent effect of pediatric cardiac progenitor cells after juvenile</span></p>
<p style="top:707.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">heart failure. Stem Cells Transl Med. 2016;5(7):883</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">92.</span></p>
<p style="top:716.5pt;left:56.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">11.</span></p>
<p style="top:716.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Albertario A, Swim MM, Ahmed EM, Iacobazzi D, Yeong M, Madeddu P,</span></p>
<p style="top:725.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">et al. Successful reconstruction of the right ventricular outflow tract by</span></p>
<p style="top:89.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">implantation of thymus stem cell engineered graft in growing swine. JACC</span></p>
<p style="top:98.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Basic to Transl Sci. 2019;4(3):364</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">84.</span></p>
<p style="top:107.8pt;left:304.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">12.</span></p>
<p style="top:107.8pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Brizard CP, Looi JYJ, Smolich JJ, Horton SB, Angerosa J, Elwood NJ, et al.</span></p>
<p style="top:116.8pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Safety of intracoronary human cord blood stem cells in a lamb model of</span></p>
<p style="top:125.7pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">infant cardiopulmonary bypass. Ann Thorac Surg. 2015;100(3):1021</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">9.</span></p>
<p style="top:135.0pt;left:304.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">13.</span></p>
<p style="top:135.0pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Davies B, Elwood NJ, Li S, Cullinane F, Edwards GA, Newgreen DF, et al. Human</span></p>
<p style="top:144.0pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">cord blood stem cells enhance neonatal right ventricular function in an ovine</span></p>
<p style="top:153.0pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">model of right ventricular training. Ann Thorac Surg. 2010;89(2):585</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">93 e4.</span></p>
<p style="top:162.3pt;left:304.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">14.</span></p>
<p style="top:162.3pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Nana-Leventaki E, Nana M, Poulianitis N, Sampaziotis D, Perrea D, Sanoudou</span></p>
<p style="top:171.3pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">D, et al. Cardiosphere-derived cells attenuate inflammation, preserve systolic</span></p>
<p style="top:180.3pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">function, and prevent adverse remodeling in rat hearts with experimental</span></p>
<p style="top:189.3pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">autoimmune myocarditis. J Cardiovasc Pharmacol Ther. 2019;24(1):70</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">7.</span></p>
<p style="top:198.6pt;left:304.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">15.</span></p>
<p style="top:198.6pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Wolter KM. Introduction to variance estimation. 2nd ed. USA: Springer-</span></p>
<p style="top:207.6pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Verlag New York; 2007. p. 448.</span></p>
<p style="top:216.8pt;left:304.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">16.</span></p>
<p style="top:216.8pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Mathias Harrer DE. Doing meta-analysis in R: a hands-on guide; 2019.</span></p>
<p style="top:226.1pt;left:304.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">17.</span></p>
<p style="top:226.1pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Hooijmans CR, Rovers MM, RBM DV, Leenaars M, Ritskes-Hoitinga M,</span></p>
<p style="top:235.1pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Langendam MW. SYRCLE</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2019;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">s risk of bias tool for animal studies. BMC Med Res</span></p>
<p style="top:244.1pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Methodol. 2014;14(43):1</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">9.</span></p>
<p style="top:253.4pt;left:304.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">18.</span></p>
<p style="top:253.4pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Sterne JA, Hern&#xe1;n MA, Reeves BC, Savovi</span><span style="font-family:LdkyhxAdvTTb5929f4c+01,serif;font-size:7.3pt;color:#131313">&#x107;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313"> J, Berkman ND, Viswanathan M,</span></p>
<p style="top:262.4pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of</span></p>
<p style="top:271.4pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">interventions. BMJ. 2016;355(4919):1</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">7.</span></p>
<p style="top:280.7pt;left:304.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">19.</span></p>
<p style="top:280.7pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">McGuinness LA. robvis: an R package and web application for visualising</span></p>
<p style="top:289.7pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">risk-of-bias assessments; 2019.</span></p>
<p style="top:298.9pt;left:304.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">20.</span></p>
<p style="top:298.9pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Moher D, Liberati A, Tetzlaff J, Altman DG, Altman D, Antes G, et al.</span></p>
<p style="top:307.9pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Preferred reporting items for systematic reviews and meta-analyses: the</span></p>
<p style="top:317.0pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">PRISMA statement. PLoS Med. 2009;6(7):272</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">97.</span></p>
<p style="top:326.2pt;left:304.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">21.</span></p>
<p style="top:326.2pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Burkhart HM, Qureshi MY, Peral SC, O</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2019;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Leary PW, Olson TM, Cetta F, et al.</span></p>
<p style="top:335.2pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Regenerative therapy for hypoplastic left heart syndrome: first report of</span></p>
<p style="top:344.2pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">intraoperative intramyocardial injection of autologous umbilical-cord blood-</span></p>
<p style="top:353.2pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">derived cells. J Thorac Cardiovasc Surg. 2015;149(3):e35</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">7.</span></p>
<p style="top:362.5pt;left:304.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">22.</span></p>
<p style="top:362.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Burkhart HM, Qureshi MY, Rossano JW, Cantero Peral S, O</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2019;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Leary PW,</span></p>
<p style="top:371.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Hathcock M, et al. Autologous stem cell therapy for hypoplastic left heart</span></p>
<p style="top:380.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">syndrome: safety and feasibility of intraoperative intramyocardial injections.</span></p>
<p style="top:389.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">J Thorac Cardiovasc Surg. 2019;158(6):1614</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">23.</span></p>
<p style="top:398.8pt;left:304.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">23.</span></p>
<p style="top:398.8pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Eitoku T, Baba K, Kondou M, Kurita Y, Fukushima Y, Hirai K, et al.</span></p>
<p style="top:407.8pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Transcoronary cell infusion with the stop-flow technique in children with</span></p>
<p style="top:416.7pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">single-ventricle physiology. Pediatr Int. 2018;60(3):240</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">6.</span></p>
<p style="top:426.0pt;left:304.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">24.</span></p>
<p style="top:426.0pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Ishigami S, Ohtsuki S, Eitoku T, Ousaka D, Kondo M, Kurita Y, et al.</span></p>
<p style="top:435.1pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Intracoronary cardiac progenitor cells in single ventricle physiology: the</span></p>
<p style="top:444.0pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">perseus (cardiac progenitor cell infusion to treat univentricular heart</span></p>
<p style="top:453.0pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">disease) randomized phase 2 trial. Circ Res. 2017;120(7):1162</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">73.</span></p>
<p style="top:462.3pt;left:304.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">25.</span></p>
<p style="top:462.3pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Pincott ES, Ridout D, Brocklesby M, McEwan A, Muthurangu V, Burch M. A</span></p>
<p style="top:471.3pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">randomized study of autologous bone marrow</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">derived stem cells in</span></p>
<p style="top:480.3pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">pediatric cardiomyopathy. J Hear Lung Transplant. 2017;36(8):837</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">44.</span></p>
<p style="top:489.6pt;left:304.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">26.</span></p>
<p style="top:489.6pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Qureshi MY, Cabalka AK, Khan SP, Hagler DJ, Haile DT, Cannon BC, et al. Cell-</span></p>
<p style="top:498.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">based therapy for myocardial dysfunction after Fontan operation in hypoplastic</span></p>
<p style="top:507.6pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">left heart syndrome. Mayo Clin Proc Innov Qual Outcomes. 2017;1(2):185</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">91.</span></p>
<p style="top:516.9pt;left:304.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">27.</span></p>
<p style="top:516.9pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Rivas J, Men&#xe9;ndez JJ, Arrieta R, Alves J, Romero MP, Garc&#xed;a-Guereta L, et al.</span></p>
<p style="top:525.9pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Utilidad de la terapia intracoronaria con c&#xe9;lulas progenitoras en pacientes</span></p>
<p style="top:534.8pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">con miocardiopat&#xed;a dilatada: &#xbf;Puente o alternativa al trasplante cardiaco? An</span></p>
<p style="top:543.8pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Pediatr. 2011;74(4):218</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">25.</span></p>
<p style="top:553.1pt;left:304.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">28.</span></p>
<p style="top:553.1pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Rupp S, Zeiher AM, Dimmeler S, Tonn T, Bauer J, Jux C, et al. A regenerative</span></p>
<p style="top:562.1pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">strategy for heart failure in hypoplastic left heart syndrome: intracoronary</span></p>
<p style="top:571.1pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">administration of autologous bone marrow-derived progenitor cells. J Hear</span></p>
<p style="top:580.1pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Lung Transplant. 2010;29(5):574</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">7.</span></p>
<p style="top:589.4pt;left:304.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">29.</span></p>
<p style="top:589.4pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Rupp S, Jux C, B&#xf6;nig H, Bauer J, Tonn T, Seifried E, et al. Intracoronary bone</span></p>
<p style="top:598.4pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">marrow cell application for terminal heart failure in children. Cardiol Young.</span></p>
<p style="top:607.4pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2012;22(5):558</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">63.</span></p>
<p style="top:616.6pt;left:304.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">30.</span></p>
<p style="top:616.6pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Sano T, Ousaka D, Goto T, Ishigami S, Hirai K, Kasahara S, et al. Impact of</span></p>
<p style="top:625.7pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">cardiac progenitor cells on heart failure and survival in single ventricle</span></p>
<p style="top:634.7pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">congenital heart disease. Circ Res. 2018;122(7):994</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">1005.</span></p>
<p style="top:644.0pt;left:304.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">31.</span></p>
<p style="top:644.0pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Tarui S, Ishigami S, Ousaka D, Kasahara S, Ohtsuki S, Sano S, et al.</span></p>
<p style="top:652.9pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Transcoronary infusion of cardiac progenitor cells in hypoplastic left heart</span></p>
<p style="top:661.9pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">syndrome: three-year follow-up of the transcoronary infusion of cardiac</span></p>
<p style="top:670.9pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">progenitor cells in patients with single-ventricle physiology (TICAP) trial. J</span></p>
<p style="top:680.0pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Thorac Cardiovasc Surg. 2015;150(5):1198</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">208 e2.</span></p>
<p style="top:689.2pt;left:304.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">32.</span></p>
<p style="top:689.2pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Zschirnt M, Jux C, Boenig H, Zeiher A, Assmus B, Khalil M, et al. Neonatal</span></p>
<p style="top:698.2pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">myocardial infarction: substantial improvement of cardiac function after</span></p>
<p style="top:707.2pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">autologous bone marrow-derived cell therapy. Clin Res Cardiol. 2019:2</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">4.</span></p>
<p style="top:716.5pt;left:304.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">33.</span></p>
<p style="top:716.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Ishigami S, Ohtsuki S, Tarui S, Ousaka D, Eitoku T, Kondo M, et al.</span></p>
<p style="top:725.5pt;left:319.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Intracoronary autologous cardiac progenitor cell transfer in patients with</span></p>
<p style="top:32.6pt;left:56.7pt;line-height:8.0pt"><span style="font-family:TqgscwAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Martinez</span><span style="font-family:XdxhkwAdvTT7329fd89.I,serif;font-size:8.0pt;color:#131313"> et al. Stem Cell Research &amp; Therapy</span><span style="font-family:MyriadPro,serif;font-size:8.0pt;color:#131313">          (2020) 11:272 </span></p>
<p style="top:32.6pt;left:492.0pt;line-height:8.0pt"><span style="font-family:TqgscwAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Page 12 of 13</span></p>


<p style="top:89.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">hypoplastic left heart syndrome: the TICAP prospective phase 1 controlled</span></p>
<p style="top:98.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">trial. Circ Res. 2015;116(4):653</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">64.</span></p>
<p style="top:107.5pt;left:56.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">34.</span></p>
<p style="top:107.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Trac D, Maxwell JT, Brown ME, Xu C, Davis ME. Aggregation of child cardiac</span></p>
<p style="top:116.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">progenitor cells into spheres activates notch signaling and improves</span></p>
<p style="top:125.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">treatment of right ventricular heart failure. Circ Res. 2019;124(4):526</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">38.</span></p>
<p style="top:134.5pt;left:56.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">35.</span></p>
<p style="top:134.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Hu X, Wang J, Chen J, Luo R, He A, Xie X, et al. Optimal temporal delivery of</span></p>
<p style="top:143.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">bone marrow mesenchymal stem cells in rats with myocardial infarction.</span></p>
<p style="top:152.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Eur J Cardio-thoracic Surg. 2007;31(3):438</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">43.</span></p>
<p style="top:161.5pt;left:56.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">36.</span></p>
<p style="top:161.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Crisostomo V, Baez-Diaz C, Maestre J, Garcia-Lindo M, Sun F, Casado JG,</span></p>
<p style="top:170.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">et al. Delayed administration of allogeneic cardiac stem cell therapy for</span></p>
<p style="top:179.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">acute myocardial infarction could ameliorate adverse remodeling:</span></p>
<p style="top:188.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">experimental study in swine. J Transl Med. 2015;13(156):1</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">16.</span></p>
<p style="top:197.5pt;left:56.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">37.</span></p>
<p style="top:197.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Xu JY, Liu D, Zhong Y, Huang RC. Effects of timing on intracoronary</span></p>
<p style="top:206.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">autologous bone marrow-derived cell transplantation in acute myocardial</span></p>
<p style="top:215.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">infarction: a meta-analysis of randomized controlled trials. Stem Cell Res</span></p>
<p style="top:224.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Ther. 2017;8(231):1</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">13.</span></p>
<p style="top:233.5pt;left:56.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">38.</span></p>
<p style="top:233.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Nitkin CR, Bonfield TL. Concise review: mesenchymal stem cell therapy for</span></p>
<p style="top:242.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">pediatric disease: perspectives on success and potential improvements.</span></p>
<p style="top:251.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Stem Cells Transl Med. 2017;6(2):539</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">65.</span></p>
<p style="top:260.5pt;left:56.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">39.</span></p>
<p style="top:260.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Brunskill SJ, Hyde CJ, Doree CJ, Watt SM, Martin-Rendon E. Route of delivery</span></p>
<p style="top:269.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">and baseline left ventricular ejection fraction, key factors of bone-marrow-</span></p>
<p style="top:278.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">derived cell therapy for ischaemic heart disease. Eur J Heart Fail. 2009;11(9):</span></p>
<p style="top:287.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">887</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">96.</span></p>
<p style="top:296.5pt;left:56.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">40.</span></p>
<p style="top:296.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Wang WE, HS CX. Potential of cardiac stem/progenitor cells and induced</span></p>
<p style="top:305.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">pluripotent stem cells for cardiac repair in ischaemic heart disease. Clini Sci.</span></p>
<p style="top:314.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2013;125(7):319</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">27.</span></p>
<p style="top:323.5pt;left:56.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">41.</span></p>
<p style="top:323.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Zwetsloot PP, AMD V, Jansen Of Lorkeers SJ, GPJ VH, Currie GL, Sena ES,</span></p>
<p style="top:332.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">et al. Cardiac stem cell treatment in myocardial infarction: a systematic</span></p>
<p style="top:341.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">review and meta-analysis of preclinical studies. Circ Res. 2016.</span></p>
<p style="top:350.5pt;left:56.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">42.</span></p>
<p style="top:350.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Fern&#xe1;ndez-Avil&#xe9;s F, Sanz-Ruiz R, Bogaert J, Plasencia AC, Gilaberte I, Belmans</span></p>
<p style="top:359.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">A, et al. Safety and efficacy of intracoronary infusion of allogeneic human</span></p>
<p style="top:368.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">cardiac stem cells in patients with st-segment elevation myocardial</span></p>
<p style="top:377.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">infarction and left ventricular dysfunction a multicenter randomized,</span></p>
<p style="top:386.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">double-blind, and placebo-controlled clinical trial. Circ Res. 2018;23(5):579</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span></p>
<p style="top:395.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">89.</span></p>
<p style="top:404.5pt;left:56.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">43.</span></p>
<p style="top:404.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Tang XL, Rokosh G, Sanganalmath SK, Tokita Y, MCL K, Shirk G, et al. Effects</span></p>
<p style="top:413.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">of intracoronary infusion of escalating doses of cardiac stem cells in rats</span></p>
<p style="top:422.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">with acute myocardial infarction. Circ Hear Fail. 2015.</span></p>
<p style="top:431.5pt;left:56.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">44.</span></p>
<p style="top:431.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">TIG VDS, Jansen Of Lorkeers SJ, Agostoni P, Van Belle E, Gyongyosi M, JPG S,</span></p>
<p style="top:440.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">et al. Human relevance of pre-clinical studies in stem cell therapy:</span></p>
<p style="top:449.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">systematic review and meta-analysis of large animal models of ischaemic</span></p>
<p style="top:458.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">heart disease. Cardiovasc Res. 2011;91(4):649</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">58.</span></p>
<p style="top:467.5pt;left:56.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">45.</span></p>
<p style="top:467.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Kemp CD, Conte JV. The pathophysiology of heart failure. Cardiovasc Pathol.</span></p>
<p style="top:476.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">2012;21:365</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">71 Elsevier.</span></p>
<p style="top:485.5pt;left:56.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">46.</span></p>
<p style="top:485.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Friedberg MK, Reddy S. Right ventricular failure in congenital heart disease.</span></p>
<p style="top:494.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Curr Opin Pediatr. 2019;31(5):604</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">10.</span></p>
<p style="top:503.5pt;left:56.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">47.</span></p>
<p style="top:503.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Thompson M, Mei SHJ, Wolfe D, Champagne J, Fergusson D, Stewart DJ,</span></p>
<p style="top:512.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">et al. Cell therapy with intravascular administration of mesenchymal stromal</span></p>
<p style="top:521.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">cells continues to appear safe: an updated systematic review and meta-</span></p>
<p style="top:530.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">analysis. EClinicalMedicine. 2020;19(100249):1</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">17.</span></p>
<p style="top:539.5pt;left:56.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">48.</span></p>
<p style="top:539.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Chamuleau SAJ, Van Der Naald M, Climent AM, Kraaijeveld AO, Wever KE,</span></p>
<p style="top:548.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">Duncker DJ, et al. Translational research in cardiovascular repair a call for a</span></p>
<p style="top:557.5pt;left:71.7pt;line-height:7.3pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">paradigm shift. Circ Res. 2018;122(2):310</span><span style="font-family:SxsscdAdvTTb5929f4c+20,serif;font-size:7.3pt;color:#131313">&#x2013;</span><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.3pt;color:#131313">8.</span></p>
<p style="top:579.1pt;left:56.7pt;line-height:10.3pt"><span style="font-family:QlgxmbAdvTTaf7f9f4f.B,serif;font-size:10.3pt;color:#131313">Publisher</span><span style="font-family:LgcqjfAdvTTaf7f9f4f.B+20,serif;font-size:10.3pt;color:#131313">&#x2019;</span><span style="font-family:QlgxmbAdvTTaf7f9f4f.B,serif;font-size:10.3pt;color:#131313">s Note</span></p>
<p style="top:590.4pt;left:56.7pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">Springer Nature remains neutral with regard to jurisdictional claims in</span></p>
<p style="top:599.3pt;left:56.7pt;line-height:7.5pt"><span style="font-family:KqdrrtAdvTTb5929f4c,serif;font-size:7.5pt;color:#131313">published maps and institutional affiliations.</span></p>
<p style="top:32.6pt;left:56.7pt;line-height:8.0pt"><span style="font-family:TqgscwAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Martinez</span><span style="font-family:XdxhkwAdvTT7329fd89.I,serif;font-size:8.0pt;color:#131313"> et al. Stem Cell Research &amp; Therapy</span><span style="font-family:MyriadPro,serif;font-size:8.0pt;color:#131313">          (2020) 11:272 </span></p>
<p style="top:32.6pt;left:492.0pt;line-height:8.0pt"><span style="font-family:TqgscwAdvTTe45e47d2,serif;font-size:8.0pt;color:#131313">Page 13 of 13</span></p>

</div>
